Postnatal $\beta_1$ Integrin Deficiency in Pancreatic Beta-Cells Impairs Function and Survival

Jason E. Peart  
*The University of Western Ontario*

Supervisor  
Rennian Wang  
*The University of Western Ontario*

Graduate Program in Pathology  
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science  
© Jason E. Peart 2017
Abstract

Integrin β1 is essential for pancreatic beta-cell development and maintenance throughout life in rodents and human fetal islets. However, the effects of a postnatal β1 integrin knockout (β1KO) specific to pancreatic beta-cells of mice is undetermined. We generated mice with CreERT recombinase specific to the mouse insulin promoter (MIP), allowing us to induce a β1KO upon injection of tamoxifen (MIPβ1KO model).

At 3-4 weeks of age tamoxifen was injected and mice were sacrificed at 8 (male) and 16 weeks (female) post-tamoxifen. MIPβ1KO mice had impaired glucose tolerance, reduced beta-cell mass and islet density. The impairment in glucose tolerance remained in aged mice. Male MIPβ1KO mice also had impaired insulin expression and secretion, along with reduced Pdx-1, p-FAK, p-ERK, and p-Akt protein levels. Insulin exocytosis proteins were also reduced in male MIPβ1KO mice. These findings demonstrate a significant role for β1 integrin in the survival and function of adult murine beta-cells.

Keywords

β1 integrin, mouse insulin promoter (MIP), Diabetes mellitus, tamoxifen-inducible, glucose tolerance test, beta-cell mass, FAK signalling
Co-Authorship Statement

The methodology described in Chapter 2 was conducted by Jason Peart in Dr. Rennian Wang’s laboratory. The following contributions were made by other members within the lab.

Jinming Li provided technical assistance with genotyping, immunofluorescence staining, and conducting western blots. Jinming Li conducted all qRT-PCR experiments presented in this dissertation. Hojun Lee aided in morphometric analyses of 16 week post-tamoxifen pancreata in Figure 3.10. Dr. Matthew Riopel conducted western blot experiments that were included in Figures 3.11B and 3.13A-D. Dr. Zhi-Chao Feng conducted western blot experiments that were used in Figures 3.13A-C and 3.13E, and contributed to the GSIS data in Figure 3.5A. All studies were designed by Dr. Rennian Wang, who generated the MIPβ1KO mice, provided insight into interpreting findings, and helped revise the final manuscript.
Acknowledgments

I would like to thank my supervisor Dr. Rennian Wang for allowing me to pursue a masters degree within her lab. Diabetes has impacted my family in so many ways, myself included, and Dr. Wang gave me the chance to contribute in a meaningful way to something I am so passionate about. In addition, Dr. Wang was always pushing for me to be more self-sufficient, a skill that essential to so many aspects of daily life, yet she was always there if I needed guidance and motivation and for that I am thankful. As a lab technician Jinming Li has provided his expertise in experimental methods countless times throughout my thesis, without him, I would not have been able to fulfill my project in its entirety. I would also like to thank all Wang Lab members for their encouraging words, assistance when needed, and their comments and feedback.

Thank you Dr. Zia Khan and Dr. Andrew Leask for being members on my committee and for providing insightful feedback regarding my project.

To my mother, Marianne, thank you for all your love and support through the years.

Lastly, thank you to the Children’s Health Research Institute and the Pathology Department at Western University for their financial support.
# Table of Contents

Abstract ........................................................................................................................................... i

Co-Authorship Statement .............................................................................................................. ii

Acknowledgments ....................................................................................................................... iii

Table of Contents ......................................................................................................................... iv

List of Tables ............................................................................................................................... vii

List of Figures .............................................................................................................................. viii

List of Appendices ....................................................................................................................... x

List of Abbreviations ................................................................................................................... xi

Chapter 1 - Introduction .............................................................................................................. 1

1.1 Significance of the study ....................................................................................................... 1

1.2 The pancreas and its development .................................................................................... 1

1.3 Beta-cells and Insulin Secretion ......................................................................................... 3

1.4 Diabetes mellitus ............................................................................................................... 7

1.5 Integrin receptors and the ECM ......................................................................................... 8

1.6 β1 integrin and islet development ...................................................................................... 11

1.7 β1 integrin in islet survival and function .......................................................................... 11

1.8 Signalling pathways involving β1 integrin in islet survival and function .................... 14

1.9 Rationale and objectives of the present study ................................................................... 18

Chapter 2 – Materials and Methods ........................................................................................... 19

2.1 Generation of the beta-cell β1 integrin knockout mouse model ....................................... 19

2.2 Mouse genotyping .............................................................................................................. 21

2.3 Tamoxifen preparation and administration ....................................................................... 23

2.4 Glucose metabolism studies ............................................................................................ 23

2.5 Islet isolation ...................................................................................................................... 24
2.6 Ex vivo GSIS .......................................................... 24
2.7 Insulin ELISA .......................................................... 24
2.8 Tissue processing and immunohistological analyses .................. 25
2.9 RNA extraction ........................................................ 30
2.10 qRT-PCR quantification ............................................. 30
2.11 Reverse transcription and cDNA synthesis .......................... 34
2.12 Protein extraction and western blot analyses ........................ 34
2.13 Statistical analyses ................................................... 35

Chapter 3 - Results ........................................................ 36
3.1 Characterization of β1 integrin expression in beta-cells of MIPβ1KO mice ...... 36
3.2 MIPβ1KO mice display impaired glucose tolerance .................. 41
3.3 Deficient glucose-stimulated insulin secretion in male but not female MIPβ1KO mice ......................................................... 46
3.4 Reduction of insulin secretory molecules in MIPβ1KO mice .......... 49
3.5 Reduced beta-cell mass in MIPβ1KO mice ............................ 56
3.6 Reduction of Pdx-1 mRNA and protein levels in male MIPβ1KO mice .......... 64
3.7 β1 integrin deficiency in beta-cells does not affect islet vasculature ....... 69
3.8 Reduction of phosphorylated-FAK, ERK1/2, and Akt protein levels with altered cell proliferation pathways in male MIPβ1KO mice ........................................ 72
3.9 Expression of other integrin subunits in male MIPβ1KO mice .......... 75
3.10 Glucose intolerance was maintained in aged MIPβ1KO mice .......... 80

Chapter 4 - Discussion ...................................................... 83
4.1 Knockdown of β1 integrin in MIPβ1KO mice .......................... 83
4.2 Do MIPβ1KO mice have impaired glucose tolerance and insulin secretion? ...... 84
4.3 Are insulin secretory molecules altered in MIPβ1KO mice? ............. 85
4.4 Is β1 integrin required for proper islet morphology? ...................... 86
4.5 Vasculature in the islets of MIPβ1KO mice ............................ 88
4.6 Signalling in MIPβ1KO mice ................................................................. 88
4.7 Aged MIPβ1KO mice and a lack of functional compensation by other integrins . 89
4.8 Limitations of the study ............................................................................ 90
4.9 Conclusions and future directions .............................................................. 92
Chapter 5 - References ..................................................................................... 95
Appendices........................................................................................................... 111
Curriculum Vitae ................................................................................................. 116
List of Tables

Table 2.1 Primary antibodies used for immunostaining and Western Blots............................. 28

Table 2.2 Sequences of primers used in qRT-PCR................................................................. 31
List of Figures

Figure 1.1 SNARE mediated insulin exocytosis in beta-cells ............................................. 6

Figure 1.2 The association of α and β integrins and their ligands ........................................ 10

Figure 1.3 β1 integrin signalling pathway ............................................................................. 17

Figure 2.1 Breeding schematic for generation of MIPβ1KO mice ........................................ 20

Figure 2.2 Representative PCR images for mouse genotyping ............................................ 22

Figure 2.3 The derivative melting curves of qRT-PCR products ........................................... 33

Figure 3.1 Confirmation of β1 integrin knockdown in 8 weeks post-tamoxifen male MIPβ1KO mice ............................................................................................................. 38

Figure 3.2 Confirmation of β1 integrin knockdown in 16 weeks post-tamoxifen female MIPβ1KO mice ............................................................................................................. 40

Figure 3.3 Metabolic analyses of 8 weeks post-tamoxifen male MIPβ1KO mice ................. 43

Figure 3.4 Metabolic analyses of 16 weeks post-tamoxifen female MIPβ1KO mice .......... 45

Figure 3.5 In vivo and ex vivo GSIS analyses ....................................................................... 48

Figure 3.6 qRT-PCR analyses of insulin exocytosis machinery mRNA in 8 weeks post- tamoxifen male MIPβ1KO mice ....................................................................................... 51

Figure 3.7 Immunofluorescence staining for insulin exocytosis proteins in 8 weeks post- tamoxifen male MIPβ1KO mice ....................................................................................... 53

Figure 3.8 qRT-PCR analysis for insulin exocytosis proteins in 16 weeks post-tamoxifen female MIPβ1KO mice ....................................................................................... 55

Figure 3.9 Morphometric analyses of 8 weeks post-tamoxifen male MIPβ1KO mice ........ 59
Figure 3.10 E-cadherin and Glut2 co-localization in 8 week post-tamoxifen male MIPβ1KO mice................................................................. 61

Figure 3.11 Morphometric analyses of 16 weeks post-tamoxifen female MIPβ1KO mice ... 63

Figure 3.12 Examination of Pdx-1 expression in 8 weeks post-tamoxifen male MIPβ1KO mice................................................................. 66

Figure 3.13 Transcription factor expression in 8 week post-tamoxifen male MIPβ1KO mice ........................................................................ 68

Figure 3.14 Measurement of islet vascularization in MIPβ1KO mice ................................................. 71

Figure 3.15 Cell signalling, proliferation, and apoptosis in 8 weeks post-tamoxifen male MIPβ1KO mice........................................................................................................ 74

Figure 3.16 qRT-PCR analyses for integrin alpha subunits in 8 weeks post-tamoxifen male MIPβ1KO mice........................................................................................................ 77

Figure 3.17 Immunofluorescence staining for integrin alpha subunits in 8 weeks post-tamoxifen male MIPβ1KO mice........................................................................................................ 79

Figure 3.18 Metabolic analyses of aged MIPβ1KO mice.............................................................. 82

Figure 4.1 Impact of the MIPβ1KO model in male mice ......................................................... 94
List of Appendices

**Appendix A:** Animal use protocol .........................................................112

**Appendix B:** Classification II laboratory approval form .............................113

**Appendix C:** Biosafety approval form .....................................................115
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt</td>
<td>v-akt murine thymoma viral oncogene</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>β1KO</td>
<td>Collagen type I alpha2 driven β1 integrin knockout mice</td>
</tr>
<tr>
<td>BP</td>
<td>Base pair</td>
</tr>
<tr>
<td>Bcl2</td>
<td>B-cell lymphoma 2</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>BW</td>
<td>Body weight</td>
</tr>
<tr>
<td>Col1a2</td>
<td>Collagen type I alpha2 chain</td>
</tr>
<tr>
<td>CreERT</td>
<td>Tamoxifen inducible Cre recombinase</td>
</tr>
<tr>
<td>CDK5</td>
<td>Cyclin-dependent kinase 5</td>
</tr>
<tr>
<td>DAPI</td>
<td>4’-6-Diamindino-2-phenylindole</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-related kinase</td>
</tr>
<tr>
<td>FAK</td>
<td>Focal adhesion kinase</td>
</tr>
<tr>
<td>FERM</td>
<td>Band 4.1, ezrin, radixin and moesin homology domain</td>
</tr>
<tr>
<td>g</td>
<td>Units of times gravity</td>
</tr>
<tr>
<td>Gcg</td>
<td>Glucagon</td>
</tr>
<tr>
<td>Glut-2</td>
<td>Glucose transporter 2</td>
</tr>
<tr>
<td>Grb2</td>
<td>Growth factor receptor-bound protein 2</td>
</tr>
<tr>
<td>GSIS</td>
<td>Glucose-stimulated insulin secretion</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
</tbody>
</table>
Hes1  hairy and enhancer of split-1
Ins   Insulin
INS-1 Rat insulinoma-1 cell line
I.P.  Intraperitoneal
IPGTT Intraperitoneal glucose tolerance test
IPITT Intraperitoneal insulin tolerance test
IR    Insulin receptor
Itg   Integrin
ISL-1 Islet-1
KO    Knockout
MAPK Mitogen-activated protein kinase
MafA  v-maf avian musculoaponeurotic fibrosarcoma homolog A
MIP   Mouse insulin promotor
MIPβ1KO Mouse insulin promoter-driven β1 integrin knockout mice
mSOS1 Son of sevenless homolog 1
Munc18-1 Mammalian homologue of unc-18
Ngn3  Neurogenin3
Nkx2.2 NK2 homeobox 2
Nkx6.1 NK6 homeobox 1
p     Phosphorylated
p110  phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
p35   NCK5a neuronal Cdk5 activator
P70s6k Ribosomal protein S6 kinase beta-1
Pax4  Paired box 4
PaSC  Pancreatic stellate cell
PBS  Phosphate buffered saline
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>Pdx-1</td>
<td>Pancreatic duodenal homeobox-1</td>
</tr>
<tr>
<td>PECAM</td>
<td>Platelet endothelial cell adhesion molecule</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>Ptf1a</td>
<td>Pancreas specific transcription factor 1a</td>
</tr>
<tr>
<td>qRT-PCR</td>
<td>Quantitative real-time reverse transcriptase PCR</td>
</tr>
<tr>
<td>RGD</td>
<td>Arg-Gly-Asp (Arginine-Glycine-Aspartic acid)</td>
</tr>
<tr>
<td>RIPβ1KO</td>
<td>Rat insulin promoter-driven β1 integrin knockout mice</td>
</tr>
<tr>
<td>RIPFAKKO</td>
<td>Rat insulin promoter-driven FAK knockout mice</td>
</tr>
<tr>
<td>RPM</td>
<td>Revolutions per minute</td>
</tr>
<tr>
<td>S473</td>
<td>Serine residue 473</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SH2</td>
<td>Src homology 2 domain</td>
</tr>
<tr>
<td>SH3</td>
<td>Src homology 3 domain</td>
</tr>
<tr>
<td>SNAP-25</td>
<td>Synaptosome associated protein-25</td>
</tr>
<tr>
<td>Stx1a</td>
<td>Syntaxin1a</td>
</tr>
<tr>
<td>Stx3</td>
<td>Syntaxin3</td>
</tr>
<tr>
<td>TBST</td>
<td>Tris-buffered saline with Tween 20</td>
</tr>
<tr>
<td>VAMP-2</td>
<td>Vesicle associated membrane protein-2</td>
</tr>
<tr>
<td>Y118</td>
<td>Tyrosine residue 118</td>
</tr>
<tr>
<td>Y397</td>
<td>Tyrosine residue 397</td>
</tr>
</tbody>
</table>
Chapter 1 - Introduction

1.1 Significance of the study

The most promising avenue for the treatment of diabetes is transplantation of pancreatic islets, yet an inadequate donor supply and short-term survival of transplanted islets are limiting factors. Finding optimal conditions for isolation of islets, transplantation, and generation of functional beta-like cells from stem cells is of critical importance to circumvent these issues. The loss of β1 integrin, a protein critical in cell-extracellular matrix (ECM) interactions, has not been studied in beta-cells of adult mice. Further understanding of the relationship of the ECM and postnatal beta-cells in their native environment will help us understand the ideal way to handle beta-cells in therapeutic conditions.

1.2 The pancreas and its development

The pancreas is a glandular organ that can be divided into two morphologically distinct regions: the exocrine and endocrine pancreas. The exocrine tissue comprises 97% of the pancreas and consists of the acinar cells which secrete a variety of digestive enzymes (proteases, lipases, and amylase) and the ductal system, responsible for transporting enzyme secretions into the duodenum. The remaining 3% of the pancreas are the highly vascularized pancreatic islets of Langerhans which were first discovered by Paul Langerhans in 1869 during his PhD studies (Langerhans, 1869). Islets are dense clusters of 5 different hormone secreting cell types (alpha-cells, beta-cells, delta-cells, gamma-cells, and epsilon-cells), that secrete the hormones glucagon, insulin, somatostatin, pancreatic polypeptide, and ghrelin respectively. Islet architecture varies between frequently studied mammalian species, with different cellular compositions in porcine, canine, murine, and human islets (Kim et al. 2009, Wang et al. 1999). Murine islets consist of a beta-cell rich core that comprises ~87% of the islet, surrounded by an outer layer of alpha-cells (7% of the islet), with the remaining cell types making up the remaining 6% (Rothers & Harlan 2004). However, human islets contain a higher percentage of alpha-cells (36%), with beta-cells accounting for 54% of the islet (Rothers
Regulation of glucose metabolism is a highly intricate process carried out through the release of glucagon and insulin. In response to hypoglycemia (low blood glucose), glucagon is released from alpha-cells and stimulates glucose production from the liver through conversion of glycogen into glucose. Alternatively, insulin is secreted by beta-cells after a meal or in hyperglycemic conditions (high blood glucose), which binds to the insulin receptor found on peripheral cells such as those in the liver, muscle, and adipose, which uptake and store excess glucose.

The pancreas is derived from an outgrowth of endodermal epithelium in the foregut that expresses Sry-related HMG box 17 protein (Sox17) (Tateishi et al. 2008). The primary transition of pancreatic development begins on mouse embryonic (e) day 8.5, where the outgrowth begins to divided into two buds known as the dorsal and ventral buds that express key transcription factors pancreatic duodenal homeobox 1 (Pdx-1) and pancreatic transcription factor 1a (Ptf1a) (Offield et al. 1996, Kagawauchi et al. 2002, Krapp et al. 1996, Hald et al. 2008. Meulen & Huising, 2015). The pancreatic buds fuse at the beginning of the secondary transition of pancreatic development (e12.5-e18.5) and forms one cohesive organ with a definitive tip region (cells destined for an exocrine cell fate expressing Ptf1a) and interior trunk region (cells destined to become either endocrine or ductal cells expressing NK6 homeobox 1 (Nkx6.1)) that is dependent on high levels of Notch activity (Afelik & Jensen 2012, Afelik et al. 2012). Most tip cells have fully differentiated into acinar cells by e15.5 (Pan et al. 2013). Within the trunk, high levels of Notch activity result in activation of hairy and enhancer of split-1 (Hes1), an inhibitor of Neurogenin 3 (Ngn3). However, lowered levels of Notch leads to a loss of Hes1 with continued activation of Sox9, an activator of Ngn3, and these cells migrate away from the ducts to commit to an endocrine cell fate (Shih et al. 2012). Endocrine cells further differentiate into the five aforementioned cell types, and it is the expression of Pdx-1, Nkx6.1 and paired box 4 (Pax4) that lead to a beta-cell fate (Collombat et al. 2003, Gannon et al. 2008, Henseleit et al. 2005, Holland et al. 2002, Shih et al. 2013, Sosa-Pineda et al. 1997). Endocrine cells begin to cluster into islet-like structures around e16 (Shih et al. 2013, Habener et al. 2005). The tertiary period of pancreatic development (e19.5 – post natal day (p) 21), is a period of remodelling where beta-cell neogenesis, proliferation and apoptosis occurs, leading to the final pancreatic structure observed in
adults (Kaung 1994, Scaglia et al. 1997). By postnatal day 21, the islets are fully mature and beta-cells are capable of maintaining normoglycemia through secretion of insulin into the plasma in response to increased blood glucose levels.

1.3 Beta-cells and Insulin Secretion

Glucose-stimulated insulin secretion is a tightly regulated process beginning with up-take of glucose by pancreatic beta-cells via the glucose transporter type 2 (Glut2) protein in rodents. Intracellular glucose leads to increased production of ATP, and an increase in the ATP/ADP ratio leading to closing of voltage-gated potassium channels, initiating depolarization of the cell (Ashcroft et al. 1984). This causes an influx of Ca\textsuperscript{2+} into the cell via L-type Ca\textsuperscript{2+} channels (Hoenig & Sharp 1986, Straub & Sharp 2002, Wollheim & Sharp 1981) and results in docking of insulin containing granules to the plasma membrane with the aid of soluble N-ethylmaleimide-sensitive attachment protein receptors (SNAREs), tethering proteins such as Rab (Ungar & Hughson 2003), and microtubule remodelling (Kalwat & Thurmond 2013). Insulin exocytosis is a biphasic phenomenon. The first phase of insulin release begins approximately 1-2 minutes after glucose is ingested. Insulin release plateaus 3-4 minutes after glucose ingestion and declines rapidly until 8 minutes afterwards as part of the K\textsubscript{ATP}-dependent (triggering) pathway (Straub & Sharp 2002). This initial phase releases insulin from an immediately available pool of insulin granules (known as the readily releasable pool), which are pre-docked insulin granules on the cell membrane (Straub & Sharp 2002, Wang & Thurmond 2009). The second phase of insulin release begins after the first, with an increasing release of insulin into the plasma that peaks at 25-30 minutes post glucose intake and this is referred to as the K\textsubscript{ATP}-independent (augmenting) pathway (Straub & Sharp 2002). During the second phase of insulin release, insulin exocytosis occurs from a pool of insulin granules known as the storage granule pool and the release of these granules can be influenced by acetylcholine and glucagon like peptide-1 (GLP-1), which lead to increased levels of diacylglycerol (DAG) and cyclic adenosine monophosphate (cyclic AMP) respectively (Straub & Sharp 2002, Wang & Thurmond 2009). Once in circulation, insulin interacts with the insulin receptor found on multiple peripheral cell types (such as liver, fat, muscle and beta-cells) and leads to the phosphorylation of insulin
receptor substrates (IRS). Phosphorylated IRS subsequently interacts with signalling pathways (e.g. phosphoinositol 3-kinase (PI3K)/Akt murine thymoma viral oncogene (Akt) and mitogen activated protein kinase (MAPK)/extracellular signal-related kinase (ERK)) that control cell metabolism, differentiation, and proliferation (Giancotti & Guo 2004). Within the beta-cell, the binding of insulin to the insulin receptor plays a positive autocrine role that regulates subsequent insulin secretion (Leibiger et al. 2001). When insulin binds to insulin receptor type A expressed on the beta-cell surface, PI3K class Ia and ribosomal protein S6 kinase beta-1 (p70s6k) are upregulated leading to enhanced insulin gene transcription (Leibiger et al. 2001). The implications of insulin and its downstream signalling are vast and vary between cell types, and the topic is beyond the scope of this thesis, however, the way by which insulin exocytosis takes place is worthy of examination.

Exocytosis is mediated by SNARE proteins, which work in a coordinated fashion. In general, a SNARE protein consists of a conserved 60-70 amino acid heptad repeat (the SNARE motif) with a transmembrane domain in the C-terminus and independently folded domains at the N-terminus (Weimbs et al. 1997, Jahn & Scheller 2006). SNAREs can be loosely defined as either target-SNAREs (t-SNAREs) which reside on the plasma membrane, or vesicle-SNAREs (v-SNAREs) which are present on vesicles (Jahn & Scheller 2006). The formation of SNARE complexes varies between organism and tissue types (Kasai et al. 2012). Studies of insulin exocytosis in beta-cells of rats and the rat cell lines HIT-T15, βTC6-F7, and RIN1056A, have shown that protein components of t-SNARES syntaxins (1-4) and synaptosome associated protein 25 (SNAP-25), and that of v-SNAREs vesicle associated membrane protein-2 (VAMP-2) and synaptotagmin III are expressed (Wheeler et al. 1996). Among the syntaxin family of proteins, syntaxin1A and syntaxin3 have been shown to be key mediators of insulin exocytosis. A Cre-mediated beta-cell specific knockout of syntaxin1A in mice lead to impaired first and second phase insulin secretion (Liang et al. 2017). Syntaxin3 siRNA in INS-1 cells and isolated mouse islets (3-6 months old) lead to a reduction in new outer insulin granules, whereas overexpression of synaxin3 enhanced both phases of insulin exocytosis (Zhu et al. 2013).
A general schematic illustrating the function of SNAREs is presented (Figure 1.1) t-SNAREs and v-SNAREs from a four-helix structure at the site of exocytosis and is dissociated by N-ethylmaleimide-sensitive factor (NSF) after exocytosis is complete (Jahn & Scheller 2006). The formation of this four-helix structure is due to the contribution of helices by individual proteins in the complex: SNAP-25 contributes two helixes, while syntaxin1A and VAMP2 each contribute one helix, allowing for membrane fusion and exocytosis (Fasshauer 2002).

Beyond the core components mentioned above, there are a multitude of other factors that are responsible for the regulation of exocytosis, two of which are Mammalian unc18 (Munc18) and synaptotagmin III. Munc18 has three known isoforms, Munc18a, Munc18b, and Munc18c (Tellam et al. 1995). Munc18a shares exact homology with Munc18, whereas Munc18b has 61% homology, and Munc18c has 51% (Tellam et al. 1995). Studies have shown that Munc18a and Munc18b have highest affinity towards syntaxins 1-3, whereas Munc18c affinity for binding is preferential to syntaxin 4 (Oh & Thurmond 2009). Studies have best characterized the relationship between Munc18 and syntaxin1A, demonstrating that Munc18 regulates Syntaxin1A by maintaining it in a closed confirmation, preventing formation of the SNARE complex by inhibiting interactions with VAMP2 and that these interactions are highly dependent on a 1:1 syntaxin:Munc18 molar ratio, and this seems to hold true for all Munc18 and syntaxin proteins (Reviewed in Thurmond 2013). Since insulin exocytosis is Ca\(^{2+}\) mediated, it is intuitive to think that part of the SNARE complex would sense calcium, and synaptotagmin III plays this role (Brown et al. 2000, Wheeler et al. 1996). Synaptotagmin III is found within secretory vesicles along with insulin, and its cytoplasmic Ca\(^{2+}\) sensing region leads to a conformational change upon influx of Ca\(^{2+}\) into the cell, allowing its interaction with syntaxin and SNAP25 on the plasma membrane (Brown et al. 2000). Impairment of insulin secretion and/or the signalling pathways at one or multiple areas leads to the development of diabetes mellitus (DM). There are several forms of DM with different treatment options available depending on the pathology of the disease.
Figure 1.1 SNARE mediated insulin exocytosis in beta-cells

A) In normal conditions the helices contributed by syntaxin1A (Stx1A), SNAP25, and VAMP-2 remain apart and Munc18a maintains Stx1A in a closed conformation. B) Influx of calcium (Ca^{2+}) into the cell results in the open conformation of Stx1A through release of inhibition by Munc18, which now aids in stabilizing the SNARE complex at the plasma membrane. At this time, the helices from Stx1A, SNAP25, and VAMP-2 come together and result in fusion of the vesicle with the plasma membrane and subsequent insulin exocytosis.
1.4 Diabetes mellitus

DM is diagnosed as one of two types based on the pathology of the disease. Type 1 diabetes (T1D) is the result of autoimmune destruction of the pancreatic beta-cells, leading to insufficient insulin production. In T1D, individuals develop severe hyperglycemia unless exogenous insulin is administered. In contrast, the development of type 2 diabetes (T2D) is multi-factorial, ranging from inefficient beta-cell mass to reduced sensitivity to insulin in peripheral tissues. T2D also results in hyperglycemia, but less severe cases can be treated with modifications in diet and increased physical activity. Medications often come in one of two forms: those that aid in maintaining sufficient beta-cell function, such as glucagon-like peptide 1 (GLP1) agonists or DPP4 inhibitors (Lamber et al. 2003, Versophl et al. 2009), or medications like metformin that target peripheral tissues to increase glucose uptake (e.g. muscle (Bailey & Puah 1986, Rosetti et al. 1990, Galsuka et al. 1994) and fat (Cigolini et al. 1984)) or decrease glucose production (e.g. liver) (Bailey & Wollen 1988, Bailey 1992, Bailey 1993). A promising avenue for the treatment for T1D is the restoration of functioning beta-cells in diabetic patients using islet transplantations. The Edmonton protocol, established during the 1990s and still in effect today, involves isolating islets from human cadaveric donors and transplanting them in the hepatic portal vein of transplant recipients (Shapiro et al. 2000). However, islet transplantation currently has many shortcomings that limit the long-term production of endogenous insulin. Transplant recipients must balance taking immunosuppressant drugs to prevent rejection while avoiding beta-cell toxicity (Zeng et al. 1993). In addition, cells are often damaged during the isolation process leading to impaired integrin and ECM interactions, induced cell death and reduced cell function, and a shortage of donor tissue, leading to inadequate beta-cell mass over time (Shapiro et al. 2000, Ryan et al. 2005). To circumvent these issues, designing optimal culture conditions for maintaining islet architecture and transplant environments for donor tissue and/or beta-like cells derived from stem cells is essential. One way to do this is to study how the integrin family of receptors, essential in cellular adhesion, interacts with the surrounding extracellular matrix (ECM) to maintain islet integrity, beta-cell function and survival.
1.5 Integrin receptors and the ECM

Integrins are heterodimeric proteins consisting of α and β subunits (18 α and 8 β subunits in mammals) that combine to form 24 different combinations (Takada et al. 2007, Barczyk et al. 2010). The ligands for integrins are proteins that comprise the extracellular matrix (ECM). The ECM consists of negatively charged glycosaminoglycans that form a porous, yet hydrated, gel-like substance in which a variety of proteins such as collagens, fibronectin, laminins, and vitronectin reside. These proteins provide stability and support for cells, while at the same time having profound influence on cell differentiation, function, proliferation, and survival (Aszódi et al. 2006, Streuli 1999, Rosso et al. 2004, Kleinmen et al. 2003). The ability of the ECM to influence the fate of cells is ultimately dependent on a variety of adhesion molecules that act to govern interactions with the environment around them. Cell adhesion molecules can be broadly defined into one of four categories: Immunoglobulin superfamily cell adhesion molecules (IGSF CAMs), integrins, cadherins, and selectins. Although there is a multitude of resources providing in-depth information on the different types of cell adhesion molecules, integrin-ECM interactions are the focus of this thesis.

Integrins can be divided into four general classes based on the extracellular ligands they bind to as dictated by the α-subunit that governs ligand binding specificity (Figure 1.2): arginine-glycine-aspartic acid (RGD) receptors (e.g., fibronectin and vitronectin), GFOGER receptors (collagens), leukocyte-specific receptors, and laminin receptors combinations (Takada et al. 2007, Barczyk et al. 2010). Integrins exist in an inactive conformation with low affinity for binding to their ligands (Springer & Dustin 2012). Inside-out signalling is a process by which integrins become activated into a high affinity ligand binding state, and talin binding to the cytoplasmic tail of the β-integrin subunit has been implicated as the key protein required for the conformational change (reviewed in Wang 2012). The binding of talin makes a direct connection between an integrin, the ECM, and the actin cytoskeleton. The kindlin family of focal adhesion proteins has been shown to activate integrins, with loss of integrin activation seen in kindlin inhibition studies (Kloeker et al. 2004, Harburger & Calderwood 2009). After the initial binding of talin and kindlins, the now activated integrin will bind to extracellular ligands leading to
outside-in signalling and resulting in further scaffolding of signalling proteins within the cell into groupings known as focal adhesions. Focal adhesions, mediated by focal adhesion kinase (FAK), can lead to a variety of downstream signalling processes involving the activation of RhoGTPases, serine/threonine kinases, and tyrosine kinases such as ERK1/2 as well as Akt (Danen & Sonneberg 2003). The multitude of proteins that coalesce together during outside-in signalling is vast and reviewed in Harburger & Calderwood (2009), but a more detailed description of β1 integrin-FAK related signalling is discussed in section 1.8.

β1 integrin is the most abundant β-integrin subunit and is expressed ubiquitously. β1 integrin associates with 12 different α subunits (α1-α11 and αv) (Barczyk et al. 2010). Signalling through β1 integrin is dependent on the cytoplasmic domain, in which a NPxY motif is present and leads to inside-out activation of β1 (Cordes et al. 2006) and outside-in activation of FAK (Wennerberg et al. 2000). β1 integrin through its affinity with 12 different α subunits, binds to all major categories of ECM proteins and is involved in actin remodelling, cell polarity, movement, and induction and maintenance of cellular differentiation and function (Brakebusch & Fassler, 2005); including cartilage and bone formation (Aszódi et al. 2006), skeletal muscle development (Burkin et al. 2001, Schwander et al. 2003), epidermis formation (Brakebusch et al. 2000), development of the cerebral cortex (Belvindrah et al. 2007), and angiogenesis (Mettouchi & Meneguzzi 2006). Researchers have begun to uncover the role of β1 integrin in the pancreas, specifically with regard to islet development, function and survival, but substantial work remains to be done.
Figure 1.2 The association of $\alpha$ and $\beta$ integrins and their ligands

The formation of potential $\alpha\beta$ integrin heterodimers is highlighted along with their preferred ligands. As indicated, $\beta 1$ integrin associates with 12 different $\alpha$ integrins allowing it to bind to all four major types of extracellular ligands (collagens, laminins, RGD motif containing proteins such as fibronectin, and leukocytes).
1.6 β1 integrin and islet development

Development of islets depend on the interactions between cells and the surrounding ECM. During rat pancreatic development, the alpha subunits that commonly associate with β1 integrin: α3, α5, and α6, all have higher mRNA levels at e18 and p28 compared to day of birth (p0) where there is a marked decrease (Yashpal et al. 2005). β1 integrin along with α3 and α6 protein also significantly increase over the period from p0 to p28 implicating its important role during the maturation and proliferative phase of rat pancreas development (Yashpal et al. 2005). Human fetal islets demonstrate a similar trend, with an increase in α3β1 and α6β1 observed by 16-20 weeks of development (Wang et al. 2005). Previous studies demonstrated that human fetal pancreatic cells migrate and interact with collagen IV matrix protein exclusively through interactions with α1β1 integrin (Kaido et al. 2004a). Similarly, αvβ1 in 19-21 week old human fetal islets has been shown to be essential for spreading and migration on vitronectin, an ECM component expressed by epithelial cells and insulin-expressing cells emerging from the ductal epithelium (Cirulli et al. 2000, Kaido et al. 2004b). In studies examining developing human and rat islets, a significant reduction of islet cell adhesion to the ECM was observed when cells were treated with a functional blocking β1 integrin antibody (Yashpal et al. 2005, Wang et al. 2005). Recently, Diaferia and colleagues (2013) generated a beta-cell specific β1 integrin knockout model using Cre recombinase downstream of the rat insulin-1 promoter (RIPβ1KO mice). This model, in which β1 integrin was knocked out from conception, resulted in a significant reduction in beta-cell mass (18% of that seen in controls) (Diaferia et al. 2013). These results show that the interaction between beta-cells and the ECM surrounding them, as mediated by β1 integrin, is essential for proper beta-cell proliferation during development and into adulthood.

1.7 β1 integrin in islet survival and function

A lot of work has been done to elucidate the role of β1 integrin in islet cell survival and function. Early studies examining isolated canine islets found that they underwent apoptosis due to destruction of the perinsular-basement membrane, but had improved survival when cultured in the presence of collagen I and fibronectin, which are two ECM proteins commonly associated with β1 integrin.
ligands of β1 integrin (Wang & Rosenberg, 1999). Most work regarding β1 in pancreatic islets has been conducted in vitro. One of the first studies found that α3β1 represents nearly half of the β1 integrins on primary and transformed (RIN-2A line) rat islet cells, and when this interaction is blocked, the islets have reduced attachment and spreading on bovine corneal ECM or ECM produced by A-431 cells (Kantengwa et al. 1997). Similarly, Parnaud (2006) found that blocking the interaction between β1 integrin and laminin-5, led to reduced insulin secretion and beta-cell spreading, whereas culturing rat islets on an 804G matrix that is rich in laminin-5 enhanced insulin secretion. Furthermore, the 804G matrix protects beta-cells from apoptosis via activation of the FAK/MAPK/ERK1/2 pathway (Hammer et al. 2004). Although the primary ligand of α3β1 is laminin, it has been shown that it can bind to a series of other matrix proteins including collagen, fibronectin, and laminin, and this is typically found in situations where another primary integrin is absent (Kantengwa et al. 1997). Studies using the insulinoma-1 cell line (INS-1), a beta-cell cancer line that secretes insulin in response to glucose within physiological ranges (Asfari et al. 1992), observed that β1 integrin associates with α1-α6 and αV in these cells, and α3β1 was the most highly expressed (Krishnamurthy et al. 2008). INS-1 cells also showed beneficial effects when cultured on collagen I and IV, whereby increased levels of spreading, survival, proliferation, and FAK activation are observed, and these beneficial effects are negated when α3β1 is blocked (Krishnamurthy et al. 2008). Studies using human fetal islets have found similar results, where interfering with β1 integrin either through blockade or siRNA leads to reduced Insulin gene expression, increased apoptosis, reduced ECM adhesion, and reduced p-FAK and p-ERK1/2 levels (Wang et al. 2005, Kaido et al. 2004b, Saleem et al. 2009). Examination of rat and human fetal islets also showed that either transfections with siRNA against β1 or utilization of a β1 immunoneutralizing antibody leads to an increase in apoptosis and a reduction in Pdx-1 and Insulin mRNA (Wang et al. 2005, Yashpal et al. 2005). Important to note is that Pdx-1 is not only responsible for proper development of the pancreas, it also plays a key role in insulin gene expression in mature beta-cells (Fujimoto and Polonsky, 2009). All of these in vitro studies highlight a role for β1 integrin in maintaining islet function and survival, however the in vivo role of β1 integrin has only recently begun to be elucidated.
In more recent years with the advancement of *in vivo* gene knockdown techniques, mouse models have been generated to study the relationship between integrins, the ECM and beta-cells. One study analyzed the role of β1 integrin by conditionally removing it in collagen Iα2-producing cells of adult mice using a CreERT-loxP system (β1KO mice) (Riopel et al. 2011). This knockout impacted beta-cells, but also affected a variety of other cell types; this includes pancreatic stellate cells (PaSC), which are fibroblast-like cells that are a major contributor of ECM proteins in the pancreas (Apte et al. 2012). In this model the pancreas became very dissociated, with some islets having no contact with exocrine cells, presumably due to the reduction in collagen fibers and connective tissue that was observed. In addition, β1KO mice developed glucose intolerance while still responding normally to exogenous insulin, indicating that hyperglycemia in mice was due to beta-cell defects (Riopel et al. 2011). The β1KO mice had reduced beta-cell mass due to a decrease in proliferation and an increase in apoptosis, a decrease in islet insulin content and reduced Pdx-1 protein levels. A decrease in FAK/ERK1/2 were also seen in β1KO mice, which corroborates previous *in vitro* studies that imply that β1 regulates survival and function of islets through this pathway (Hammer et al. 2004, Krishnamurthy et al. 2008, Saleem 2009). Since the ablation of β1 integrin was not specific to beta-cells, it is unclear whether the loss of β1 integrin played a direct or indirect role in islet cell function and survival.

As previously mentioned, the RIPβ1KO model has been generated for use as a beta-cell specific β1 knockout mouse model (Diaferia et al. 2013). However, the knockout is present in beta-cells as soon as the *Insulin* gene is transcribed at the beginning of embryonic development. Despite the significantly reduced beta-cell mass in adult RIPβ1KO mice (~18% of that seen in wild-type), islet architecture was unchanged and insulin content was significantly increased in the remaining beta-cell population (Diaferia et al. 2013). These islets lacking β1 integrin also secreted significantly more insulin in response to glucose during an IPGTT and resulted in maintenance of normoglycemia. One possible explanation proposed is that β3 and β5 integrins have crosstalk capabilities that can compensate for β1 integrin when it is blocked or genetically ablated (Diaferia et al. 2013). The ability for these integrin subunits to compensate, and the fact that the knockout was induced at conception, leaves ample time during development for this
compensatory response. Although other integrins may have been able to maintain the functional role of beta-cells, this study shows that β1 is a key regulator of cellular proliferation in beta-cells. Positive regulators of cell-cycle arrest were up-regulated in RIPβ1KO mice, such as cyclin dependent kinase 1A, cyclin dependent kinase 5 regulatory subunit associated protein 1, and ERK-dependent tumour suppressors (e.g., deleted in malignant brain tumors 1). Paralleling these findings was a reduction in cyclin D1, a protein required for progression through the G1 phase of the cell cycle that has been established to be essential in postnatal beta-cell growth (Kushner et al. 2005). The formation of focal-adhesions is the way by which integrins regulate outside-in signalling, and the RIPβ1KO model showed a significant decrease in p-ERK1/2 and p-Akt within these islets. The mechanism by which these proteins regulate beta-cells and the specific proteins involved are discussed now.

1.8 Signalling pathways involving β1 integrin in islet survival and function

When integrins are activated they interact with the band 4.1, ezrin, radixin and moesin homology (FERM) domain on FAK (Lim et al. 2008), which leads to autophosphorylation of tyrosine residue 397 either through direct interaction with integrins or through the phosphorylation of FAK tyrosine residues 576 and 577 by proto-oncogene tyrosine kinase Src (Schaller 2001). Src can be activated by a variety of tyrosine phosphatases (Brakebusch & Fassler, 2003) and it interacts with the focal adhesion complex through its SH2 domain which binds to FAK autophosphorylation domains, or through is SH3 domain which interacts with paxillin (Clark & Brugge, 1995). The binding of Src leads to recruitment of SH2-SH3 adaptor proteins through further modifications of FAK (Clark & Brugge, 1995), one of which being the phosphorylation of FAK at tyrosine 925 (p-FAK<sup>Y925</sup>), leading to the subsequent binding of growth factor receptor-bound protein 2 (Grb2) and the Ras guanine nucleotide exchange factor mSOS1 (son of sevenless homolog 1) (Giancotti & Ruoslahti, 1999). This leads to downstream phosphorylation of kinases Ras and rapidly accelerated fibrosarcoma (Raf), which causes activation of the MAPK/ERK1/2 pathway. ERK1/2 can regulate cell proliferation and survival in a variety of ways once activated. ERK1/2 has
been shown to induce NCK5a neuronal CDK5 activator (p35) expression, a known activator of cyclin-dependent kinase 5 (CDK5) (Harada et al. 2001). Together, CDK5 and ERK1/2 can promote cell cycle progression and prevent apoptosis through phosphorylating the anti-apoptotic protein b-cell lymphoma 2 (Bcl2) on residues threonine 56, 74 or serine 84 which promotes the release of apoptotic proteins from the mitochondria (Wang et al. 2006, Stupack & Cheresh, 2002). Additionally, ERK1/2 can prevent caspase-mediated apoptosis by inhibiting caspase 9 activity (Allan et al. 2003).

One group of researchers generated a rat insulin 1 promoter-driven FAK knockout (RIPFAKKO) and found that when beta-cell FAK is diminished, CDK5, ERK1/2 and Bcl2 activity are significantly reduced along with decreased beta-cell mass (Cai et al. 2012). This finding brings together the multitude of studies that have previously shown links between reduced beta-cell survival and decreased FAK/ERK1/2 pathway signalling due to an impairment of normal β1 function or levels (Hammer et al. 2004, Krishnamurthy et al. 2008, Saleem 2009, Riopel et al. 2011, Diaferia et al. 2013).

As mentioned before, the activation of Src by FAK can lead to the recruitment of SH2-SH3 adaptor proteins, one of which is the p85 subunit of PI3K, which allows for the catalytic activity of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110) (Xia et al. 2004). Downstream of PI3K/p110 activation, Akt becomes phosphorylated at serine 473 (p-AktS473) (McLean et al. 2005, Xia et al. 2004). The activation of AktS473 has been shown to prevent apoptosis in a variety of different manners, like that of ERK1/2 through the regulation of capase-9 and BAD which directly interacts with Bcl2, preventing its anti-apoptotic properties (Song et al. 2005). In addition, reduced p-AktS473 signaling was found in RIPβ1KO mice, which suggests a role in the reduction in beta-cell mass and increased cell death (Cai et al. 2012). The RIPFAKKO model also showed a significant reduction in p-AktS473 which could be playing a similar role in this model regarding cell survival (Cai et al. 2012).

The role of FAK mediated signalling has also been shown to play a role in glucose stimulated insulin secretion through cytoskeletal remodelling (Kalwat & Thurmond 2013, Ronadas et al. 2011, Rondas et al. 2012, Cai et al. 2012). Once activated by FAK phosphorylation, paxillin directly interacts with the cytoskeleton through interactions
with vinculin and actopaxin, and these interactions are partly responsible for actin remodeling through depolymerization (reviewed in Turner 2000). A recent study used MIN6B1 cells (Rondas et al. 2012) to knock down β1 integrin or FAK and found that glucose-induced disruption of F-actin, which is required for proper granule movement to the plasma membrane, was hindered. Additionally, phosphorylated paxillin at tyrosine 118 (p-paxillin\textsuperscript{Y118}), along with p-ERK1/2 were decreased during glucose stimulation along with the glucose-induced activation of the Akt/AS160 signalling pathway (Rondas et al. 2012). Using rat beta-cells or isolated islets (Rondas et al. 2011) and hindering FAK or paxillin function, similar results were noted along with a reduction in SNARE proteins such as SNAP25 and syntaxin 1. Using the RIPFAKKO mouse model, a reduction in FAK also lead to reduced p-paxillin\textsuperscript{Y118} and colocalization of it with SNAP25 and syntaxin 1 on the plasma membrane was reduced (Cai et al. 2012). These findings highlight the essential role of FAK mediated signalling not only in beta-cell survival but also in mediating insulin exocytosis through cytoskeletal remodeling (Figure 1.3)
Figure 1.3 β1 integrin signalling pathway

Outside-in signalling as mediated by β1 integrin is due to the formation of focal adhesion complexes. When focal adhesion kinase (FAK) becomes phosphorylated it leads to the activation of downstream signalling molecules through a kinase cascade resulting in regulation of cell proliferation, survival, differentiation and glucose metabolism. Additionally, the focal adhesion complex is responsible for cytoskeletal remodelling essential for insulin exocytosis.
1.9 Rationale and objectives of the present study

The rationale of this project is to elucidate the role of β1 integrin in beta-cells of adult mice without the confounding variables of development (Diaferia et al. 2013) or non-beta cell specificity (Riopel et al. 2011) seen in previous mouse models. A new inducible β1KO model where CreERT is downstream of the mouse insulin-1 promoter (MIP) was generated (MIPβ1KO) to remove these variables and determine the precise role of β1 integrin in beta-cells of adult mice.

Objective

To utilize the MIPβ1KO mouse model to elucidate the role of β1 integrin specifically in the beta-cells of adult mice.

Hypothesis

Beta-cell specific β1 integrin knockout in adult mice will lead to glucose intolerance, impaired beta-cell function, and survival.

Specific Questions

1. Do adult MIPβ1KO mice display impaired glucose tolerance and insulin secretion?
2. Are insulin secretory molecules altered in MIPβ1KO mice?
3. Does a beta-cell specific knockout of β1 integrin in adult mice lead to reduced beta-cell mass and increased beta-cell death?
4. Are there alterations in transcription factor expression in MIPβ1KO mice?
5. Does a beta-cell specific knockout of β1 integrin in adult mice affect islet vascularization?
6. Are associated intracellular signaling pathways affected in MIPβ1KO islets?
7. Does α integrin expression change in MIPβ1KO mice?
8. Do aged MIPβ1KO mice recover from the initial knockout of β1 integrin?
Chapter 2 – Materials and Methods

2.1 Generation of the beta-cell β1 integrin knockout mouse model

The mouse insulin 1 promoter-driven Cre recombinase mouse line (MIP-CreER) was a gift from Dr. Louis Philipson’s laboratory (University of Chicago, Chicago, IL, USA) (Tamarina et al. 2014). To verify the specificity of the CreER transgene, MIP-CreER mice were crossed with B6;129S6-Gt(Rosa)26Sor^{tm9(CAG-tdTomato)Hze/J} mice (Jackson Laboratory, Stock # 007905). Cre expression in the MIP-CreER mice excised the LoxP-stop-LoxP signal 5’ to the tdTomato gene and activated expression of the red fluorescence reporter protein exclusively in beta-cells of isolated islets (Trinder et al. 2016). To generate the beta-cell specific β1 integrin knockout (MIPβ1KO) mouse line, C57Bl/6 mice with a LoxP floxed β1 integrin gene (B6;129-Igbi^tm1Efu/J), obtained from Jackson Laboratory (Stock #004605) were crossed with MIP-CreER mice within our vivarium (Victoria Research Laboratories, Victoria Hospital, London, ON, CA), producing MIP-CreER^+/−;β1itg^fl/+ mice. The MIP-CreER^+/−;β1itg^fl/+ mice were subsequently mated to generate the tamoxifen inducible β1 integrin knockout experimental mouse model MIPβ1KO (MIP-CreER^+;β1itg^fl/) and control mice (MIP-CreER^+;β1itg^fl/+ and MIP-CreER^+;β1itg^+/+) (Figure 2.1). All protocols were approved by the Animal Use Subcommittee at the University of Western Ontario in accordance with the guidelines of the Canadian Council of Animal Care (Appendix A).
**Figure 2.1 Breeding schematic for generation of MIPβ1KO mice**

Heterozygote mice obtained from the initial crossing of *MIP-CreERT* mice with *B6;129-Itgb1tm1Efu/J* mice lead to six different potential phenotypic combinations. The experimental mice that were used were the control mice (*MIP-CreERT*⁺⁺;Itgb1⁺/+ and *MIP-CreERT*⁻⁻;Itgb1⁻⁻, blue) and MIPβ1KO mice (*MIP-CreERT*⁻⁻;Itgb1⁻⁻/⁻, red). Percentages of the likelihood of any given genotype are listed.
2.2 Mouse genotyping

For genotyping, approximately 1-3mm of tail from each mouse was collected at weaning, then dissolved and heated in 50 μL base solution (25 mM NaOH; 0.2 mM EDTA) at 95°C for 30 minutes, and allowed to cool to room temperature for 1 hour. Subsequently, 50 μL of Tris-HCl (pH 5.5) was then added to neutralize each sample and were centrifuged at 15000 x g for 1 minute. Polymerase chain reactions (PCR) were used to confirm the genotype using the following primers: *MIP* (5’-CCT GGC GAT CCC TGA ACA TGT CCT-3’) and *CreERT* (5’-TGG ACT ATA AAG CTG GTG GGC AT-3’), whereas *β1itgfl/fl* was detected using *oIMR1906* (5’-CGG CTC AAA GCA GAG TGT CAG TC-3’) and *oIMR1907* (5’-CCA CAA CTT TCC CAG TTA GCT CTC-3’). A 2% agarose gel with ethidium bromide was used to verify the PCR amplicons. The gels were run at 80 V for 90 minutes and imaged using the Gene Genius Bio Imaging System (SynGene, Frederick, MD, USA) along with GeneSnap 7.12 software (SynGene). *MIPCreERT*+ mice were identified by the corresponding *MIPCreERT* DNA fragment at 268 base pairs (BP) (Figure 2.2A), while *β1itg+/+* and *β1itgfl/fl* mice produced a single DNA fragment size of either 160bp or 280bp, respectively (Figure 2.2B).
Figure 2.2 Representative PCR images for mouse genotyping

A) MIPCreERT\textsuperscript{+} positive mice are indicated by one distinct band located at 268bp. B) Itgβ1 mice are either heterozygous for the wildtype and mutant alleles and display two bands at 160bp and 280bp (Itgβ1\textsuperscript{+/fl}, yellow arrow), homozygous for the wildtype alleles at 160bp (Itgβ1\textsuperscript{+/+}, blue arrow) or homozygous for the mutant alleles at 280bp (Itgβ1\textsuperscript{fl/fl}, red arrow).
2.3 Tamoxifen preparation and administration

Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% ethanol to a final concentration of 300 mg/mL. The sample was heated at 60°C and vortexed until the tamoxifen was completely dissolved. For injections, the ethanol-suspended tamoxifen was diluted in corn oil (Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of 30 mg/mL. Mice were injected intraperitoneally (I.P.) at 3-4 weeks of age for three consecutive days at a dosage of 4 mg per 20 g of body weight (BW).

2.4 Glucose metabolism studies

An intraperitoneal glucose tolerance test (IPGTT) was conducted at 4, 8, 16 (females only), or 25-35 weeks post-tamoxifen injection in MIPβ1KO and control mice to measure the response of mice to high glucose levels. For the IPGTT, glucose (D- (+)-glucose; dextrose; Sigma-Aldrich, St. Louis, MO, USA) was administered intraperitoneally at a dose of 2 mg/g of BW after a 16 hour overnight fast, and blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes post injection (as reported in Riopel et al. 2011). Area under the curve (AUC) was used to quantify glucose responsiveness using units of ([mmol/L x minute]) (Allison et al. 1995, Krishnamurthy et al. 2007).

Glucose-stimulated insulin secretion (GSIS) was performed at 8 weeks (males) or 16 weeks (females) post-tamoxifen, following an overnight fast of 16 hours. Plasma blood samples via tail vein were collected at 0 minutes before an IP glucose injection (2 mg/g BW), and at 5 and 35 minutes after glucose loading (Riopel et al. 2011). The blood samples were centrifuged for 20 minutes at 15871 x g at 4°C and plasma was stored at -20°C.

An intraperitoneal insulin tolerance test (IPITT) was conducted at 8 weeks (male) and 16 weeks (female) in MIPβ1KO and control mice to insulin sensitivity. Following a 4 hour fast (starting at 9AM), 1 U/kg BW of human insulin (Humalin, Eli Lilly, Toronto, Ontario, Canada) was administered via IP injection, and blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes post injection (Riopel et al. 2011). Data
was expressed as the percent change from basal blood glucose levels and AUC was used for quantification [(mmol/L x minute)] (Allison et al. 1995, Krisnamurthy et al. 2007, Feng et al. 2013).

2.5 Islet isolation

Islets from both MIPβ1KO and control mice at 8 weeks and 16-week post-tamoxifen injection were isolated using the following methodology: the common bile duct was sutured closed via surgical string in close proximity to the duodenum and 3 mL of collagenase V (1 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was injected via bile duct to perfuse the pancreas. The pancreas was then dissociated in a 15 mL falcon tube with 3 mL dissociation buffer (Hank’s balanced salt solution with HEPES) and incubated in a 37°C hot water bath for 30 minutes. Islet purification was performed using a Ficoll gradient as previously described (Wang et al. 2004), and processed for RNA or protein extraction as well as for ex vivo GSIS.

2.6 Ex vivo GSIS

For ex vivo GSIS, duplicate samples with 10 islets per experimental group were hand-picked and incubated in RPMI 1640 (11% glucose) overnight for recovery culture. The overnight culture media was collected for basal insulin secretion levels. Islets were washed in glucose-free media and incubated in the following manner: a low glucose media (2.2 mM) for 1 hour, then in a high glucose solution (22 mM) for 1 hour, and a final 1 hour incubation in an additional low glucose media (2.2 mM) (Feng et al. 2012). The media from each incubation stage was collected and stored at -20°C, and islets were washed and stored in PBS at -20°C. Insulin secretion and content were measured using the Mouse Ultrasensitive Insulin Enzyme Linked Immunosorbent Assay (ELISA) kit (ALPCO, Salem, NH, USA).

2.7 Insulin ELISA

Islet insulin secretion and content was measured using a mouse ultrasensitive insulin ELISA kit (ALPCO, Salem, NH, USA) with a sensitivity of 0.15 ng/mL, according to the manufacturer’s instructions. Insulin release was expressed as ng/mL. A static glucose
stimulation index in isolated islets was calculated by dividing the insulin output from the high glucose (22 mM) incubation by the insulin output during the low glucose (2.2 mM) incubation.

2.8 Tissue processing and immunohistological analyses

Mice were sacrificed at 8 weeks (male) or 16 weeks (female) post-tamoxifen, or at 25-35 weeks post-tamoxifen for aged cohorts, and their pancreata were fixed in 4% paraformaldehyde overnight at 4°C (Fisher Scientific Company, Ottawa, ON, Canada). Tissue was washed in phosphate buffered saline (PBS) and subjected to a series of dehydration steps (70%-100% ethanol), toluene, and paraffin wax (Fisher Scientific Company, Ottawa, ON, Canada) using the Shandon Citadel™ Tissue Processor 1000 (Thermo Electron Corporation, Waltham, MA, USA). Embedded tissue was cut into 3 μm thick sections using the Leica RM2245 microtome (Leica Biosystems, Concord, ON, Canada) and placed on a heat plate at 37°C overnight.

For immunofluorescence staining, slides were deparaffinized and rehydrated starting with three separate xylene washes and a series of ethanol (100% to 70%) solutions, and finally washed in PBS. To recover epitopes masked during paraformaldehyde fixation, slides were placed in a sodium citrate antigen retrieval solution (pH 6.0) (Bouwens et al. 1997) and heated in a microwave for 20 minutes. A 10% normal goat serum solution (Invitrogen, Frederick, MD, USA) was applied for 30 minutes at room temperature to prevent non-specific antibody binding. Primary antibodies were applied using the manufacturers’ recommended dilutions listed in Table 2.1, and incubated overnight at 4°C. Secondary antibodies were used at a 1:50 dilution as follows: fluorescein isothiocyanate (FITC anti-mouse, anti-rat, or anti-rabbit) or TexRed (anti-mouse, anti-rat, or anti-rabbit) (Jackson ImmunoResearch, West Grove, PA, USA). Nuclei were stained with DAPI (4’-6-diamidino-2-phenylindole) (Sigma-Aldrich, St. Louis, MO, USA) at a dilution of 1:1000 (coverslips were subsequently secured and the slides were stored at -20°C away from light exposure. Images were obtained using the Leica DMIRE2 fluorescence microscope (Improvision, Lexington, MA, USA) and quantified using Image-Pro software (MediaCybernetics, Rockville, MD, USA).
Immunohistochemical staining was conducted for detection of the transcription factor MafA. The rehydration and blocking steps were the same as previously mentioned. For secondary antibody application, streptavidin-biotin horseradish peroxidase complex and aminoethyl carbazole substrate kit was used (Invitrogen, Frederick, MD, USA) after incubation with the primary antibody. The slides were counter-stained using Hematoxylin (Thermo Scientific, Burlington, ON, Canada). Images were obtained with the Leica upright light microscope (Improvision, Lexington, MA, USA) and quantified using Image-Pro software (MediaCybernetics Rockville, MD, USA).

An islet was defined as any cluster of 3 or more insulin+ cells with at least one non-beta cell. Islet density (islet number per mm²) was obtained by measuring all islets on the pancreatic sections and dividing that number by the total pancreas area. Islet size was calculated by measuring all islets’ area (μm²) per tissue section and then sorted into subgroups based on size, with data being expressed as a percentage of total islet number. Alpha and beta-cell mass was determined by manually tracing the glucagon+ or insulin+ area and pancreatic section area, and the data was calculated as follows: alpha-cell mass (mg) = (glucagon+ area x pancreas mass)/pancreas area; beta-cell mass (mg) = (insulin+ area x pancreas mass)/pancreas area, as previously described (Wang et al. 1994).

Quantification of beta-cell nuclear proteins was conducted using double immunofluorescence staining for Ki67, Pdx-1, Nkx6.1, Nkx2.2 or Isl-1 with insulin. A total of 10 random islets were selected per sample and analyzed using Image-Pro software (MediaCybernetics). Insulin+ cells that co-stained with a nuclear transcription factor (TF) were quantified and expressed as a percentage of double positive labelling cells divided by the total number of insulin+ cells.

Platelet endothelial cell adhesion molecule (PECAM) was used as a co-stain with insulin to identify vasculature in islets. For analyses, 10 random islets were selected and their capillaries and total islet size was manually traced. Islet capillary area was measured by taking the combined area of all capillaries within an islet and dividing it by the total islet area, and was expressed as a percentage. The average islet capillary diameter was measured.
as the total diameter of all islet capillaries divided by the total number of capillaries and expressed as a mean (μm²) (Feng et al. 2015).
<table>
<thead>
<tr>
<th>Primary Antibodies</th>
<th>Dilution</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Akt Rabbit polyclonal</td>
<td>1:3000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-Cyclin D1 Mouse monoclonal</td>
<td>1:2000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-E-Cadherin Rabbit polyclonal</td>
<td>1:200</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-ERK Rabbit polyclonal</td>
<td>1:3000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-FAK Rabbit polyclonal</td>
<td>1:1000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-Glucagon Rabbit polyclonal</td>
<td>1:800</td>
<td>Sigma-Aldrich (St Louis, MO, USA)</td>
</tr>
<tr>
<td>Anti-Glut2 Rabbit polyclonal</td>
<td>1:200</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-Insulin Mouse monoclonal</td>
<td>1:800</td>
<td>Sigma-Aldrich (St Louis, MO, USA)</td>
</tr>
<tr>
<td>Anti-Insulin Rabbit polyclonal</td>
<td>1:50</td>
<td>Santa Cruz (Santa Cruz, CA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin α3 Rabbit polyclonal</td>
<td>1:50</td>
<td>Chemicon (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin α5 Rabbit polyclonal</td>
<td>1:50</td>
<td>Chemicon (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin α6 Rabbit polyclonal</td>
<td>1:50</td>
<td>Santa Cruz (Santa Cruz, CA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin αV Rabbit polyclonal</td>
<td>1:100</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin β1 Rabbit polyclonal</td>
<td>1:500*</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-Integrin β1 Rat monoclonal</td>
<td>1:100</td>
<td>Milipore (Etobicoke, ON, CA)</td>
</tr>
<tr>
<td>Anti-Islet1 Mouse monoclonal</td>
<td>1:100</td>
<td>DSHB (Iowa City, IA, USA)</td>
</tr>
<tr>
<td>Anti-Ki67 Rabbit polyclonal</td>
<td>1:100</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-MafA Rabbit polyclonal</td>
<td>1:100</td>
<td>Bethyl Laboratory (Montgomery, TX, USA)</td>
</tr>
<tr>
<td>Anti-Munc18-1 Rabbit polyclonal</td>
<td>1:100</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Antibody</td>
<td>Type</td>
<td>Dilution</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td>Anti-Nkx2.2</td>
<td>Mouse monoclonal 1:100</td>
<td>DSHB (Iowa City, IA, USA)</td>
</tr>
<tr>
<td>Anti-Nkx6.1</td>
<td>Mouse monoclonal 1:100</td>
<td>DSHB (Iowa City, IA, USA)</td>
</tr>
<tr>
<td>Anti-PARP</td>
<td>Rabbit polyclonal 1:1000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-Pdx-1</td>
<td>Rabbit polyclonal 1:800 1:2000*</td>
<td>Dr. Wright (University of Vanderbilt, Nashville, TN, USA)</td>
</tr>
<tr>
<td>Anti-PECAM</td>
<td>Rabbit polyclonal 1:200</td>
<td>Santa Cruz (Santa Cruz, CA, USA)</td>
</tr>
<tr>
<td>Anti-phospho-Akt (Ser473)</td>
<td>Mouse monoclonal 1:2000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-phospho-Cleaved PARP</td>
<td>Rabbit polyclonal 1:1000*</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-phospho-ERK (Thr202/Tyr204)</td>
<td>Rabbit polyclonal 1:3000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-phospho-FAK (Tyr397)</td>
<td>Rabbit polyclonal 1:2000*</td>
<td>Cell Signaling (Temecula, CA, USA)</td>
</tr>
<tr>
<td>Anti-SNAP25</td>
<td>Mouse monoclonal 1:50</td>
<td>Santa Cruz (Santa Cruz, CA, USA)</td>
</tr>
<tr>
<td>Anti-Syntaxin 1A</td>
<td>Mouse monoclonal 1:50</td>
<td>Santa Cruz (Santa Cruz, CA, USA)</td>
</tr>
<tr>
<td>Anti-VAMP2</td>
<td>Rabbit polyclonal 1:200</td>
<td>Abcam (Cambridge, MA, USA)</td>
</tr>
<tr>
<td>Anti-β-actin</td>
<td>Mouse monoclonal 1:5000*</td>
<td>Sigma-Aldrich (St Louis, MO, USA)</td>
</tr>
</tbody>
</table>

* Indicates dilution factor used when conducting a western blot. DSHB stands for Developmental Studies Hybridoma Bank at the University of Iowa.
2.9 RNA extraction

RNA was extracted from isolated mouse islets via the RNAqueous-4 PCR Kit as per the manufacturer’s instructions (Ambion, Austin, TX, USA). Cell lysate was then vortexed intermittently and washed with 64% ethanol (Life Technologies, Carlsbad, CA, USA). A collection filter was used to isolate RNA (Life Technologies, Carlsbad, CA, USA), and heated elution solution (Life Technologies, Carlsbad, CA, USA) was applied to collect the RNA from the filter. DNA contamination was eliminated by DNase treatment (Life Technology, Carlsbad, CA, USA). The concentration of RNA was measured using a Multiskan Spectrometer (Thermo Scientific, Burlington, ON, Canada), and only samples with a concentration greater than 0.1 μg/μL were used. RNA quality was confirmed by observation of a 28S and 18S band when run on a 1% agarose ethidium bromide infused gel.

2.10 qRT-PCR quantification

Quantitative real-time reverse transcriptase PCR (qRT-PCR) was conducted with 0.1 μg of cDNA using the iQ SYBR Green Supermix kit (Bio-Rad Laboratories, Mississauga, ON, Canada), along with 0.5 μL forward and reverse primers (Table 2.2). To verify primer specific amplification, the reactions were performed by omitting reverse transcriptase (RT-), cDNA, or DNA polymerase and no reaction bands were observed. Reactions were run using the Bio-Rad CFX Connect™ real-time PCR detection system (Bio-Rad Laboratories, Mississauga, ON, Canada) and analyzed using CFX Manager software (Bio-Rad Laboratories). Relative mRNA levels were calculated using the 2^(-ΔACT) method, where ΔCT is the difference between the threshold cycle of a given cDNA transcript and the internal standard gene 18S rRNA subunit cDNA (Schmittgen et al. 2008). The derivative melting curves were analyzed to assess amplification specificity of the target gene sequence (Figure. 2.3).
<table>
<thead>
<tr>
<th>Primer</th>
<th>Accession</th>
<th>Sequence 5’-3’ (Sense/Antisense)</th>
<th>Fragment Size (bp)</th>
<th>Annealing Temp (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucagon</td>
<td>NM_008100.4</td>
<td>GAT CAT TCC CAG CTT CCC AG CGG TTC CTC TTG GTG TTC AT</td>
<td>163</td>
<td>56.5</td>
</tr>
<tr>
<td>Ins1&amp;2</td>
<td>NM_008386.3</td>
<td>GGC TTC TTC TAC ACA CCC A</td>
<td>182</td>
<td>53.9</td>
</tr>
<tr>
<td></td>
<td>NM_008387.4</td>
<td>CAG TAG TTC TCC AGC TGG TA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itga3 (α3)</td>
<td>NM_013565.2</td>
<td>GCC ATC CGC CCT GCT ACT GT AGT ACG GGC TGC AAG TTG TCC</td>
<td>219</td>
<td>60.9</td>
</tr>
<tr>
<td>Itga5 (α5)</td>
<td>NM_010577.3</td>
<td>GGC ACC CAA GGC TAA CAC TA CGA ACT GTT GCT CCG AAC CA</td>
<td>204</td>
<td>57.7</td>
</tr>
<tr>
<td>Itga6 (α6)</td>
<td>NM_008397.3</td>
<td>TGG CTT CCT CGT TTG GCT ATG GAA TCG GCT TCA CAT TAC TC</td>
<td>168</td>
<td>54.2</td>
</tr>
<tr>
<td>ItgaV (αV)</td>
<td>NM_008402.2</td>
<td>ACC TGG ACG TCG AAA GTC CC CCG GCG GCT GGA TGA GCA TT</td>
<td>194</td>
<td>59.4</td>
</tr>
<tr>
<td>Itgb1 (β1)</td>
<td>NM_010578.2</td>
<td>GGC AAC AAT GAA GCT ATC GTG TTC GGA TTG ACC ACA GTT GTC</td>
<td>257</td>
<td>55.1</td>
</tr>
<tr>
<td>Pdx1</td>
<td>NM_008814.3</td>
<td>CCA CCC CAG TTT ACA AGC TCG GTA GGC AGT ACG GGT CCT CT</td>
<td>324</td>
<td>57.5</td>
</tr>
<tr>
<td>Snap25</td>
<td>NM_011428.3</td>
<td>GGC TTC ATC CGC AGG GTA AC CTG GCG ATT CTG GGT GTC AAT</td>
<td>138</td>
<td>58.9</td>
</tr>
<tr>
<td>Gene</td>
<td>Accession</td>
<td>Sequence</td>
<td>Length</td>
<td>Percentage</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td>Syntaxin1A</td>
<td>NM_016801.3</td>
<td>AAG GAC AGC GAT GAC GAC GAC TTC GGC AAT CTT GTC AAT AA</td>
<td>114</td>
<td>55.5</td>
</tr>
<tr>
<td>Syntaxin3</td>
<td>NM_001025307.1</td>
<td>GTC GGC ACA AGG ACA TCG TA TGT TCT CAA TGC GGT CAA TCA</td>
<td>117</td>
<td>56.5</td>
</tr>
<tr>
<td>Vamp2</td>
<td>NM_009497.3</td>
<td>GAG CGG GAC CAG AAG TTG TC TCC ACC AGT ATT TGC GCT TG</td>
<td>109</td>
<td>57.8</td>
</tr>
<tr>
<td>18S</td>
<td>NR_003278.3</td>
<td>GTA ACC CGT TGA ACC CCA TTC CCA TCC AAT CGG TAG TAG CG</td>
<td>151</td>
<td>55.6</td>
</tr>
</tbody>
</table>
Figure 2.3. The derivative melting curves of qRT-PCR products.

The derivative melting curves (arrows) of glucagon and insulin show that qRT-PCR assays have amplified specific target sequences.
2.11 Reverse transcription and cDNA synthesis

Oligo-(dT) (500 μg/ml), DEPC, and random hexamers (3000 ng/mL) were added to the RNA and heated for 5 minutes at 60°C and then cooled down to 4°C for 5 minutes using the GeneAmp PCR System 2400 (Applied Biosystems INC., Foster City, CA, USA). Afterwards, 4 μL of 5x buffer, 2 μL of DTT, 2 μL of 10 mM dNTPs and 0.5 μL of RNAsin was mixed together and added to the RNA sample. The GeneAmp PCR System (Applied Biosystems) was used to heat samples in the following order: 42°C for 90 minutes, 94°C for 5 minutes, and 4°C for 60 minutes. SuperScript® II Reverse Transcriptase (200 units) (Invitrogen) was added with the samples at 42°C and a final concentration of 6 μg/ 8 μL was obtained by dilution with sterile H2O and stored at -20°C. Samples omitting SuperScript® II Reverse Transcriptase were used as negative controls.

2.12 Protein extraction and western blot analyses

Isolated islets were lysed in Nonident-P40 lysis buffer (Nonident-P40, phenylmethylsulfonyl fluoride, sodium orthovanadate) (Sigma-Aldrich, St. Louis, MO, USA) and a Complete™ protease-inhibitor cocktail tablet (Roche Applied Science, Quebec City, QC, Canada) using a sonicator, and then placed on ice for 30 minutes afterwards and spun down at 15871 x g for 20 minutes at 4°C before storage at -80°C (Riopel et al. 2011). A Bradford protein assay was conducted using the Bio-Rad dye reagent (Bio-Rad Laboratories, Mississauga, ON, Canada). Bovine serum albumin (BSA) standard concentrations at 0, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/mL were used for the standard curve. 10 μL of each standard and 1 μL of sample (added to 9 μL of sterile H2O) was pipetted onto a micro titer plate in duplicate. Once the dye was added to the samples, they were placed on a shaker for 20 minutes at room temperature. A Multiskan Spectrum spectrophotometer (Thermo Scientific, Burlington, ON, Canada) was used to read the optical density values at 595 nm.

Protein was loaded at a concentration ranging from 15-20 μg into either a 7.5%, 10%, or 12.5% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) resolving gel.
Electrophoresis was conducted at a rate of 40 V as it ran through the 4% stacking gel, and 80 V for the remaining duration required to run to the bottom of the resolving gel. Nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, ON, Canada) were used for protein transfer. The transfer was conducted at 250 mA for 150 minutes in an ice encased chamber containing transfer buffer (195 mM glycine, 25 mM Tris, and methanol at a volume of 20%). Membranes were treated with Ponceau S for approximately 1 minute, whereas gels were treated with Coomassie Blue for 30 minutes at room temperature to subjectively assess overall protein transfer. Membranes were then washed in Tris-buffered saline containing 0.1% Tween-20 (Zymed Laboratories, San Fran, CA, USA) to remove the Ponceau S. Blocking buffer was applied to the membranes for 30 minutes at room temperature (5% non-fat dairy milk, containing 2.5 mL 1x TBST and 50 μL NP-40 (Zymed Laboratories)). Primary antibodies (Table 2.1) were applied for 2 hours at room temperature, or overnight at 4°C, and the membranes were washed 3 times for 10 minutes in 1x TBST wash buffer prior to incubation with secondary antibodies. Anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibodies were applied for 1 hour at room temperature (Cell Signaling Temecula, CA, USA). Proteins were detected using ECL™-Plus Western Blot detecting reagents (Perkin-Elmer, Wellesley, MA, USA) and imaged using the Versadoc Imaging System (Bio-Rad Laboratories). Image Lab (Bio-Rad Laboratories) was used to quantify the bands using densitometry and data were normalized to appropriate loading controls (e.g., β-Actin).

2.13 Statistical analyses

Data are expressed as means ± SEM. Statistical significance was determined using an unpaired student's t-test (GraphPad software; La Jolla, CA, USA). Differences were considered statistically significant when $p < 0.05$. 
Chapter 3 - Results

3.1 Characterization of β1 integrin expression in beta-cells of MIPβ1KO mice

To confirm and quantify the knockdown of β1 integrin in MIPβ1KO mice, both mRNA and protein from isolated islets were analyzed. qRT-PCR analysis showed a significant reduction of β1 integrin mRNA (p < 0.01 vs. control, Figure 3.1A) and protein level (p < 0.01, Figure 3.1B) of approximately 60% in the male MIPβ1KO islets compared to controls at 8 weeks post-tamoxifen. Immunofluorescence staining was used to qualitatively examine β1 integrin knockdown and showed a reduction of β1 integrin in the islets of MIPβ1KO mice compared to control mice (Figure 3.1C). However, the reduction of β1 integrin mRNA in isolated female MIPβ1KO islets at 16 weeks post-tamoxifen showed no statistical significance due to high variability among the samples (Figure 3.2A). Both western blot and immunofluorescence staining showed slightly reduced levels of β1 integrin protein in the islets of female MIPβ1KO mice compared to controls (Figure 3.2B,C).
**A**

![Graph showing relative $\beta_1$ integrin mRNA expression](image)

**B**

![Western blot of $\beta_1$ integrin](image)

**C**

![Immunofluorescence images of control and MIP$\beta_1$KO](image)
Figure 3.1 Confirmation of β1 integrin knockdown in 8 weeks post-tamoxifen male MIPβ1KO mice

A) qRT-PCR for β1 integrin mRNA and B) western blot analysis for β1 integrin protein in control and MIPβ1KO islets, with a representative blot shown. C) Representative double immunofluorescence staining for β1 integrin (green) and insulin (red) in the islets of control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-5/group) **p < 0.01 vs. control group.
**A**

Relative β1 integrin mRNA expression (fold vs. control)

**B**

Relative β1 integrin protein level (fold vs. control)

**C**

β1 Integrin  
Insulin  
Merged

Control

MIPβ1KO

**B**

β1 integrin  
130kDa; 110kDa  
β-Actin 42kDa
Figure 3.2 Confirmation of β1 integrin knockdown in 16 weeks post-tamoxifen female MIPβ1KO mice

A) qRT-PCR for β1 integrin mRNA and B) western blot analysis for β1 integrin protein in control and MIPβ1KO islets, with a representative blot shown. C) Representative double immunofluorescence staining for β1 integrin (green) and insulin (red) in the islets of control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3/group).
3.2 MIPβ1KO mice display impaired glucose tolerance

Fasting blood glucose levels were taken along with body weight measurements to assess phenotypic abnormalities. Male MIPβ1KO mice at 8 weeks post-tamoxifen showed no change in fasting blood glucose and BW compared to control mice (Figure 3.3A,B). However, fasting blood glucose level in female MIPβ1KO mice at 16 weeks post-tamoxifen were significantly elevated (p < 0.05, Figure 3.4A) with no change in BW (Figure 3.4B). IPGTT and IPITT tests were performed to assess glucose metabolism. Male MIPβ1KO mice subjected to an IPGTT showed statistically significant elevations in blood glucose at 15, 30, and 90 minutes post glucose injection which corresponded with an significant increase in the overall AUC (p < 0.05, Figure 3.3C). Impaired glucose tolerance was also observed in female MIPβ1KO mice at 16 weeks post-tamoxifen with a significant elevation of blood glucose at 30 minutes, and a significant increase in the overall AUC (p < 0.05, Figure 3.4C). To examine if peripheral insulin sensitivity was altered in MIPβ1KO mice, an IPITT was conducted and both MIPβ1KO mice and control mice responded in a similar fashion at all time points with unchanged AUC in all testing groups (Figure 3.3D and Figure 3.4D).
Figure 3.3 Metabolic analyses of 8 weeks post-tamoxifen male MIPβ1KO mice

A) Fasting blood glucose (16 hours) and B) body weight of male control and MIPβ1KO mice. C) IPGTT and D) IPITT analyses and their corresponding AUC data for control and MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-8/group). *p < 0.05 vs. control group.
**A**

Fasting blood glucose (mmol/L)

- Control
- MIPβ1KO

**B**

Body weight (g)

- Control
- MIPβ1KO

**C**

Blood glucose levels (mmol/L) vs. Minutes after i.p. glucose injection

- Control
- MIPβ1KO

**D**

% Change of basal blood glucose vs. Minutes after i.p. insulin injection

- Control
- MIPβ1KO

AUC (mmol/L x min)
Figure 3.4 Metabolic analyses of 16 weeks post-tamoxifen female MIPβ1KO mice

A) Fasting blood glucose (16 hours) and B) body weight of female control and MIPβ1KO mice. C) IPGTT and D) IPITT analyses and their AUC for control and MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-8/group). *p < 0.05 vs. control group.
3.3 Deficient glucose-stimulated insulin secretion in male but not female MIPβ1KO mice

Because the MIPβ1KO mice showed impairment in glucose tolerance, glucose-stimulated insulin secretion (GSIS) was measured both in vivo and ex vivo to determine beta-cell functional responsiveness. An in vivo GSIS test was performed in male MIPβ1KO mice at 8 weeks post-tamoxifen and showed significantly lower levels of plasma insulin at 5 and 35 minutes post glucose injection, along with significantly elevated blood glucose at 35 minutes when compared to littermate controls (p < 0.05, Figure 3.5A). To directly assess beta-cell function, isolated islets from male MIPβ1KO and control mice were incubated overnight and basal insulin levels were measured using an insulin ELISA. Basal insulin secretion in male MIPβ1KO islets was significantly lower with ~50% the amount of insulin compared to control islets (p < 0.001, Figure 3.5C). When male MIPβ1KO islets were subjected to an ex vivo GSIS test, a significant reduction of insulin secretion in response to glucose challenge was observed compared to control islets (p < 0.05, Figure 3.5E). The impairment in proper blood glucose management during fasting and under high glucose loading conditions in female MIPβ1KO mice at 16 weeks post-tamoxifen led to the subsequent analyses of insulin release in vivo and ex vivo using isolated islets. Female MIPβ1KO mice subjected to a GSIS test had similar levels of plasma insulin as controls (Figure 3.5B). Isolated islets of female MIPβ1KO also had no change in basal insulin secretion (Figure 3.5D), and no significant reduction during the ex vivo GSIS test was observed (Figure 3.5F).
**A** Male
- Control Blood Glucose
- MIP 1KO Blood Glucose
- Control Insulin
- MIP 1KO Insulin

Blood glucose levels (mmol/L)

Minutes after i.p. glucose injection

**B** Female
- Control Blood Glucose
- MIP 1KO Blood Glucose
- Control Insulin
- MIP 1KO Insulin

Blood glucose levels (mmol/L)

Minutes after i.p. glucose injection

**C** Basal insulin secretion (ng/mL)

Control MIPb1KO

**D** Basal insulin secretion (ng/mL)

Control MIPb1KO

**E** Glucose stimulation index

Control MIPb1KO

**F** Glucose stimulation index

Control MIPb1KO
**Figure 3.5 In vivo and ex vivo GSIS analyses**

*In vivo* GSIS assay showing blood glucose and plasma insulin levels after 16-hour fast in A) male and B) female control and MIPβ1KO mice. Basal insulin secretion from isolated islet of C) male and D) female control and MIPβ1KO mice. *Ex vivo* insulin secretion in response to high glucose conditions in isolated islet of E) male and F) female control and MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (*n* = 4-7/group). *p* < 0.05; ***p* < 0.001 vs. control group.
3.4 Reduction of insulin secretory molecules in MIPβ1KO mice

An investigation into the molecules involved in exocytosis of insulin granules was conducted. A significant reduction in the mRNA of \textit{Snap25} (p < 0.05, \textbf{Figure 3.6A}) and \textit{Vamp2} (p < 0.01, \textbf{Figure 3.6B}) was observed in male MIPβ1KO islets at 8 weeks post-tamoxifen compared to controls. Immunofluorescence staining showed a clear reduction in SNAP25 and VAMP2 in beta-cells in alignment with the reduction in mRNA in male MIPβ1KO mice (\textbf{Figure 3.7A,B}). Both \textit{Syntaxin 1A} (\textit{Stx1a}) and \textit{Syntaxin 3} (\textit{Stx3}) mRNA in male MIPβ1KO islets was unchanged compared to control mice (\textbf{Figure 3.6C,D}). Immunofluorescence staining for Munc18 showed a reduction in the beta-cells of male MIPβ1KO mice (\textbf{Figure 3.7C}). Female MIPβ1KO mice at 16 weeks post-tamoxifen showed a similar trend with reductions of \textit{Snap25}, \textit{Vamp2}, \textit{Syntaxin1A} and \textit{Syntaxin3} mRNA, but it was not statistically different compared to controls (\textbf{Figure 3.8A-D}).
A) Relative Snap25 mRNA expression (fold vs. control)
B) Relative Vamp2 mRNA expression (fold vs. control)
C) Relative Sxta mRNA expression (fold vs. control)
D) Relative Sx3 mRNA expression (fold vs. control)
Figure 3.6 qRT-PCR analyses of insulin exocytosis machinery mRNA in 8 weeks post-tamoxifen male MIPβ1KO mice

Relative gene expression of control and male MIPβ1KO mice for A) Snap25, B) Vamp2, C) Syntaxin1A (Stx1a), and D) Syntaxin3 (Stx3). Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-4/group). *p < 0.05 vs. control.
Figure 3.7 Immunofluorescence staining for insulin exocytosis proteins in 8 weeks post-tamoxifen male MIPβ1KO mice

Representative immunofluorescence staining images with separated fluorescent channels for A) Snap25, B) Vamp2, and C) Munc18 (green), with insulin (red) in control and MIPβ1KO mice. Nuclei were stained with DAPI (blue) \((n=3/group)\). Scale bar: 25 μm.
Figure 1: Relative mRNA expression (fold vs. control) for different genes in control and MIPβ1KO conditions.

A) Relative Snap25 mRNA expression

B) Relative Vamp2 mRNA expression

C) Relative Stx1a mRNA expression

D) Relative Stx3 mRNA expression
Figure 3.8 qRT-PCR analysis for insulin exocytosis proteins in 16 weeks post-tamoxifen female MIPβ1KO mice

Relative mRNA expression of control and female MIPβ1KO mice for A) Snap25, B) Vamp2, C) Syntaxin1A (Stx1a), and D) Syntaxin3 (Stx3). Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3/group).
3.5 Reduced beta-cell mass in MIPβ1KO mice

Morphological studies of male MIPβ1KO (8 weeks post-tamoxifen) and control pancreata showed that the overall architecture of the pancreas was unaltered and islets remained intact in tight clusters (Figure 3.9A). Morphometric analyses of islet density (islets per mm²) showed a significant reduction in male MIPβ1KO mice compared to the controls (p < 0.05, Figure 3.9B). When islets were grouped based on their size, it was found that there were significantly more small islets (501-2500 μm²), and less of the large islets (2501-10000 μm²) in the male MIPβ1KO pancreas (p < 0.05, Figure 3.9C). The decrease in size seen in large islets was clearly related to a significant decrease (~60%) in beta-cell mass in male MIPβ1KO mice (p < 0.05, Figure 3.9D), yet there was no accompanied reduction in alpha-cell mass (Figure 3.9E). Because a reduction in beta-cell mass was seen, insulin (Ins) mRNA was examined using isolated islets from male MIPβ1KO mice and was found to be significantly decreased compared to control islets (p < 0.05, Figure 3.9F). There was no change in the expression of glucagon (Gcg) mRNA in male MIPβ1KO mice (Figure 3.9G). Immunofluorescence staining was also used to examined E-cadherin (Figure 3.10A) and Glut2 (Figure 3.10B), proteins known to be important in maintaining beta-cell function and glucose-sensing, and no change was detected in male MIPβ1KO mice.

Morphological examination of female MIPβ1KO mice 16 weeks post-tamoxifen and control pancreata showed relatively smaller islets (Figure 3.11A); however, quantitative assessment of islet number per mm² of pancreas was not significantly altered in female MIPβ1KO mice (Figure 3.11B). When examining female MIPβ1KO islet size, there was a significant increase in very small islets (< 500 μm²), but larger islets did not display any clear reduction (p < 0.05, Figure 3.11C). Although islet density and size was not significantly impacted, there was a significant reduction in beta-cell mass (~50%), implying that there is either a reduction in beta-cell proliferation or increase in apoptosis in female MIPβ1KO mice compared to controls (p < 0.01, Figure 3.11D). Unlike that seen in male MIPβ1KO, female MIPβ1KO showed a significant reduction in alpha-cell mass (p < 0.05, Figure 3.11E). Both Ins and Gcg mRNA levels were reduced in isolated...
islets of female MIPβ1KO and control mice, but significance was not reached due to high variability among the samples (Figure 3.11F,G).
**Control** MIP β1 KO

### A

Glucagon/Insulin/DAPI

### B

![Graph showing islet number per mm²](image)

### C

![Graph showing islet size distribution](image)

### D

![Graph showing beta-cell mass](image)

### E

![Graph showing alpha-cell mass](image)

### F

![Graph showing relative insulin mRNA expression](image)

### G

![Graph showing relative glucagon mRNA expression](image)
Figure 3.9 Morphometric analyses of 8 weeks post-tamoxifen male MIPβ1KO mice

A) Representative immunofluorescence images showing insulin+ staining (red) and DAPI (blue) in control (left) and MIPβ1KO (right) mice. Scale bar: 200 µm. B) Islet number, C) islet size, D) beta-cell mass and E) alpha-cell mass of control and MIPβ1KO mice (n = 5-6/group). qRT-PCR analysis for F) Insulin and H) Glucagon mRNA of control and MIPβ1KO mice (n = 3-4/group). Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM. *p < 0.05 vs. control group.
Figure 3.10 E-cadherin and Glut2 co-localization in 8 week post-tamoxifen male
MIPβ1KO mice

Representative immunofluorescence staining images for islets of control and MIPβ1KO
mice for A) cell adhesion molecule e-cadherin (green) and insulin (red) and B) glucose-
sensing transporter Glut2 (green) and insulin (red). Nuclei were stained with DAPI (blue)
(n = 3/group) Scale bar: 25 µm.
A

Glucagon/Insulin/DAPI

B

Islet number per mm$^2$

C

Islet size / total islets (%)

D

Beta-cell mass (mg)

E

Alpha-cell mass (mg)

F

Relative insulin mRNA expression (fold vs. control)

G

Relative glucagon mRNA expression (fold vs. control)
Figure 3.11 Morphometric analyses of 16 weeks post-tamoxifen female MIPβ1KO mice

A) Representative immunofluorescence images showing insulin⁺ staining (red) and DAPI (blue) in control (left) and MIPβ1KO mice (right) mice. Scale bar: 200 µm. B) Islet number, C) islet size, D) beta-cell mass and E) alpha-cell mass of control and MIPβ1KO mice (n = 5/group). qRT-PCR analysis for F) Insulin and H) Glucagon mRNA of control and MIPβ1KO mice (n = 3/group). Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM. *p < 0.05 vs. control group.
3.6 Reduction of Pdx-1 mRNA and protein levels in male MIPβ1KO mice

Because of the significant impairment in glucose tolerance and insulin secretion in male MIPβ1KO mice 8 weeks post-tamoxifen, it was important to elucidate the underlying mechanism behind the dysfunction. Pdx-1 is an important regulator of insulin transcription (Ahlgren et al. 1998) and both mRNA and protein levels were significantly reduced in the β1KO model reported by Riopel (2011). The level of Pdx-1 mRNA in the islets of male MIPβ1KO mice was significantly reduced by ~40% when compared to control mice (p < 0.01, Figure 3.12A), along with a significant reduction in Pdx-1 protein level as measured by western blot (p < 0.01, Figure 3.12B). Immunofluorescence staining for Pdx1 in beta-cells of male MIPβ1KO mice was consistently less intense than controls (Figure 3.12C). We further examined transcription factors Nkx6.1 (Figure 3.13A), NK2 homeobox2 (Nkx2.2) (Figure 3.13B), Islet-1 (Isl-1) (Figure 3.13C) and v-maf avian musculoaponeurotic fibrosarcoma homolog A (Mafa) (Figure 3.13D) using dual immunofluorescence staining or immunohistochemical staining, and found relatively similar staining intensities displayed between male MIPβ1KO mice and control mice.
Figure 3.12 Examination of Pdx-1 expression in 8 weeks post-tamoxifen male MIPβ1KO mice

A) Pdx-1 mRNA expression and B) Pdx-1 protein levels in control and MIPβ1KO mice with a representative blot shown (n = 3-6/group). C) Representative immunofluorescence images for Pdx-1 (green), insulin (red) and DAPI (blue) in control and MIPβ1KO mice. Scale bar: 25 µm. Black bars; control, white bars; MIPβ1KO group. Data are expressed as mean ± SEM. ** p < 0.01 vs. control.
Figure 3.13 Transcription factor expression in 8 week post-tamoxifen male MIPβ1KO mice

Representative immunofluorescence images and quantification for A) Nkx6.1 (green) and insulin (red), B) Nkx2.2 (green) and insulin (red), C) Isl-1 (red) and insulin (green). D) Representative immunohistochemical staining for MafA (red) in control and MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 2-5/group). Scale bar = 25 µm.
3.7 β1 integrin deficiency in beta-cells does not affect islet vasculature

Immunofluorescence staining for PECAM and insulin showed no discernable differences in the vascularization of islets in 8 weeks post-tamoxifen male MIPβ1KO mice (Figure 3.14A). Islet capillary area and diameter showed no significant changes relative to controls (Figure 3.14B,C). Just as with the male MIPβ1KO mice, female MIPβ1KO mice 16 weeks post-tamoxifen had no obvious changes in islet vasculature (Figure 3.14D). Quantitative assessment of female MIPβ1KO islet capillary area and diameter also showed no changes compared to control mice (Figure 3.14E,F). These findings demonstrate that vasculature is unaltered in MIPβ1KO mice.
A

PECAI/Insulin/DAPI

Control  MIP\textbeta \text{1KO}

Male

B

Islet capillary area/islet area (%)

Control  MIP\textbeta \text{1KO}

C

Capillary diameter (\textmu m)

Control  MIP\textbeta \text{1KO}

D

PECAM/Insulin/DAPI

Control  MIP\textbeta \text{1KO}

Female

E

Islet capillary area/islet area (%)

Control  MIP\textbeta \text{1KO}

F

Capillary diameter (\textmu m)

Control  MIP\textbeta \text{1KO}
Figure 3.14 Measurement of islet vascularization in MIPβ1KO mice

A) Representative immunofluorescence staining of PECAM (green), insulin (red) and DAPI (blue) in control and male MIPβ1KO mice. Scale bar: 25 µm. Quantification of blood vessel area (B) and density (C) in control and male MIPβ1KO mice. D) Representative immunofluorescence staining of PECAM (green), insulin (red), and DAPI (blue) in female control and MIPβ1KO mice. Scale bar: 25 µm. Blood vessel area (E) and density (F) quantification in female control and MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 2-5/group).
3.8 Reduction of phosphorylated-FAK, ERK1/2, and Akt protein levels with altered cell proliferation pathways in male MIPβ1KO mice

FAK and its downstream signalling molecules ERK1/2 and Akt have been shown to be important in beta-cell proliferation, survival, and function (Riopel et al. 2011, Feng et al. 2015). In line with results reported by Riopel (2011) and Diaferia (2013) using the β1KO and RIPβ1KO models respectively, there was a significant reduction in p-FAK$^{Y397}$ (p < 0.001, Figure 3.15A) and p-ERK1/2 (p < 0.05, Figure 3.15B) in male MIPβ1KO mice 8 weeks post-tamoxifen compared to controls. A significant decrease in p-Akt$^{S473}$ was also observed in male MIPβ1KO mice (p < 0.05, Figure 3.15). Analysis of the proliferation marker cyclin D1 in isolated islets from male MIPβ1KO mice showed a significant reduction compared to control islets (p < 0.05, Figure 3.15D). The protein level of the apoptotic marker c-PARP was also significantly increased in male MIPβ1KO islets (p < 0.05, Figure 3.15E). Immunofluorescence staining for the proliferative marker Ki67 in male MIPβ1KO islets was similar to that of controls (Figure 3.15G).
Figure 3.15 Cell signalling, proliferation, and apoptosis in 8 weeks post-tamoxifen male MIPβ1KO mice

Western blot analyses for A) p-FAK$^{Y397}$, B) p-ERK1/2, and C) p-Akt$^{S473}$, with representative blots shown for control and MIPβ1KO mice. D) Cyclin D1 and E) c-PARP protein levels with representative blots from control and MIPβ1KO mice. F) Representative immunofluorescence staining for Ki67 (green), insulin (red) and DAPI (blue), and quantification of Ki67$^+$ beta-cells for control and MIPβ1KO mice. Scale bar: 25 μm. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-11/group). *p < 0.05, **p < 0.001 vs control.
3.9 Expression of other integrin subunits in male MIPβ1KO mice

The examination of other integrin subunits was conducted to see if there was any upregulation in a compensatory manner due to the knockdown of β1 integrin in male MIPβ1KO mice 8 weeks post-tamoxifen. qRT-PCR analysis of α3 integrin mRNA showed no change (Figure 3.16A), however qualitative assessment of immunofluorescence staining for the subunit in male MIPβ1KO mice showed an increase (Figure 3.17A). mRNA for α5 integrin was relatively unchanged (Figure 3.16B) and immunofluorescence staining showed co-localization to alpha-cells with no obvious differences compared to controls (Figure 3.17B). mRNA levels for α6 and αV integrins showed no change (Figure 3.16C,D), and there was no clear differences in immunofluorescence staining for these integrins in male MIPβ1KO islets compared to controls (Figure 3.17C,D).
Figure 3.16 qRT-PCR analyses for integrin alpha subunits in 8 weeks post-tamoxifen male MIPβ1KO mice

Relative mRNA expression for: A) α3 integrin, B) α5 integrin, C) α6 integrin, and D) αV integrin in control and male MIPβ1KO mice. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 3-4/group).
Figure 3.17 Immunofluorescence staining for integrin alpha subunits in 8 weeks post-tamoxifen male MIPβ1KO mice

Representative immunofluorescence images with separated fluorescence channels for A) α3 integrin, B) α5 integrin, C) α6 integrin, and D) αV integrin (green) with insulin (red) in control and male MIPβ1KO mice. Nuclei were stained with DAPI (blue) (n=3/group). Scale bar: 25 μm.
3.10 Glucose intolerance was maintained in aged MIPβ1KO mice

To investigate whether MIPβ1KO mice could recover overtime as an adaptive response through increased expression of other integrins, aged MIPβ1KO mice at 25-35 weeks post-tamoxifen were examined. Aged male MIPβ1KO mice showed significantly elevated blood glucose after an overnight fast (p < 0.05, Figure 3.18A). Aged female MIPβ1KO mice also displayed relatively high fasting blood glucose levels, but there was no statistical significance compared to control mice (Figure 3.18B). Similar BW was observed in all aged groups (Figure 3.18C,D). IPGTT in aged male MIPβ1KO mice showed significantly elevated blood glucose levels at 60, 90 and 120 minutes after glucose injection with a significantly increased overall AUC when compared to control mice (p < 0.05-0.01, Figure 3.18E). An IPGTT in the aged female MIPβ1KO mice showed significantly elevated blood glucose levels at 30, 60, 90, and 120 minutes after glucose load (p < 0.05-0.01) along with a significantly increased AUC (p < 0.05 – 0.01, Figure 3.18F).
Figure 3.18 Metabolic analyses of aged MIPβ1KO mice

Fasting blood glucose of aged A) male and B) female control and MIPβ1KO mice. Body weight for aged C) male and D) female control and MIPβ1KO mice. E) IPGTT analysis of control and aged male MIPβ1KO mice and the corresponding AUC. F) IPGTT analysis of control and aged female MIPβ1KO mice, with the corresponding AUC. Black bars: control, white bars: MIPβ1KO group. Data are expressed as mean ± SEM (n = 6-14/group). *p < 0.05, **p < 0.01 vs. control.
Chapter 4 - Discussion

This study aimed to examine the role of β1 integrin in the beta-cells of adult mice using a beta-cell specific knockout of β1 integrin. Based on previous literature, I hypothesized that the MIPβ1KO mice would have impaired glucose tolerance and insulin secretion (through a reduction of SNARE proteins involved in insulin exocytosis), reduced beta-cell mass, and a reduction in FAK/MAPK/ERK and PI3K/Akt activity. My key findings confirmed my hypothesis.

4.1 Knockdown of β1 integrin in MIPβ1KO mice

Tamoxifen was given I.P. at 4 mg/20g BW for 3 consecutive days to produce MIPβ1KO mice. This regimen was adapted from the dosage given in Furuyama et al. (2011), where 4 mg/20 g BW was given I.P. for 5 days every 48 hours. This dosage demonstrated sufficient CreER activation as indicated by x-gal staining, along with no apparent organ damage and no abnormalities within plasma samples (Furuyama et al. 2011). Consecutive dosages at such a high concentration of tamoxifen has not be used in any publications and it was observed that some male, and many female mice from both control and KO groups, became ill after the second and third round of tamoxifen administration. Various reports have been published regarding the potential toxicity of tamoxifen (Denk et al. 2015, Huh et al. 2012, Bersell et al. 2013, Phillips DH 2011). It is also possible that the surviving mice were not all receiving a consistent I.P. dose of tamoxifen, and that those receiving the higher end of the dose are the ones that did not survive. One potential factor for variability in tamoxifen dosages are human error, such as leakage of the corn oil-based tamoxifen solution from the injection site, as well as the potential for injecting into areas other than the peritoneal cavity, such as the abdomen, spleen, or even the pancreas itself.

It was apparent that a sufficient knockdown was achieved in male MIPβ1KO mice, as verified by western blot (~40% knockdown), qRT-PCR (~60% knockdown), and an observable difference in immunofluorescence staining intensity of β1 integrin. These values are comparable to those achieved in Riopel (2011, 2013), and despite a larger dosage of tamoxifen used in this study (4 mg/ 20 g BW for 3 consecutive days compared
to 1mg tamoxifen for 5 consecutive days), it did not lead to any clear differences in knockdown between the models. However, female mice responded differently to the specified tamoxifen dose, which requires further elaboration. Although mRNA levels showed a slight decrease in β1 integrin along with a clear reduction of β1 integrin in insulin positive cells as assessed by immunofluorescence staining, isolated islet protein showed no change compared to controls. Riopel (2011, 2013) also noted that female mice did not display as drastic a phenotype as male mice. Female MIPβ1KO mice showed no significant decreases in glucose tolerance until 16 weeks of age, demonstrating there is some underlying protective factor in female mice that becomes lessened with age. Along this rationale of thinking, it is possible that the less overt phenotype observed in female mice throughout this study is primarily due to differences in the degree of β1 knockdown due to dosage, age, or potentially through the protective effect of estrogen that has been observed in beta-cells of streptozotocin and alloxan treated female mice (Kilic et al. 2014, Le et al. 2006). It was apparent that the tamoxifen dosage used was sufficient to induce a significant knockdown of β1 integrin in the pancreatic beta-cells of male MIPβ1KO mice, and although there are no previous studies reporting gender differences in tamoxifen sensitivity (see Feil et al. 2009 for a review), it was clear that induction of the β1 integrin knockdown did not increase with the dosage of tamoxifen given. The higher dosage used in this study as opposed to that used in Riopel (2011, 2013) was not sufficient to induce a significant reduction of β1 integrin in female MIPβ1KO mice.

4.2 Do MIPβ1KO mice have impaired glucose tolerance and insulin secretion?

Unlike the previous study utilizing a global β1KO model (Riopel 2011, 2013), there was no difference in body weight, pancreatic weight and macrostructure between MIPβ1KO and control mice. Although fasting blood glucose levels were only significantly elevated in female MIPβ1KO mice and not males, both genders showed significantly elevated blood glucose levels during an IPGTT. Even though these findings are not in alignment with data published by Diaferia (2013), it is important to note that the knockout of β1 integrin in our study was conducted in adult mice, without any time for compensation by
other integrins during embryonic and postnatal (p0-p21) development. The findings of glucose intolerance observed are more in agreement with published studies by Riopel (2011) and Cai (2012), where either knockdown of β1 integrin in adults or knockout of FAK from conception leads to impaired glucose tolerance in adult life. Because there was no change in insulin tolerance in MIPβ1KO mice, the prolonged elevation in blood glucose levels in both male and female mice are either indicative of a defect in insulin secretion, a reduction in beta-cell mass, or both. As such, an in vivo GSIS assay was conducted and plasma insulin levels were examined. Male MIPβ1KO mice had significantly reduced plasma insulin levels after I.P glucose injection, indicating an overall decrease in total insulin production. However, female mice did not display a similar trend. To further assess if it was beta-cell dysfunction or some other underlying mechanism leading to reduced plasma insulin after an administered glucose load, islets were subjected to an ex vivo GSIS assay. Just as in Cai (2012), isolated islets had reduced insulin secretion in response to an increased concentration of glucose in the media. Basal insulin secretion levels were also reduced in male MIPβ1KO indicating some impairment normal levels of insulin secretion. To understand what was leading to this impairment, an examination of exocytotic proteins involved in insulin secretion was conducted.

4.3 Are insulin secretory molecules altered in MIPβ1KO mice?

It was clear in male MIPβ1KO mice that there was reduced VAMP-2 and SNAP-25 at both the mRNA and protein level. This deficiency leads to impaired insulin vesicle docking, as the interaction between VAMP-2 on the membrane of vesicles and SNAP-25 on the plasma membrane is a requirement for proper vesicle fusion (Fasshauer 2002). Just as studies have shown that focal adhesion remodelling is required for proper glucose stimulated insulin secretion through FAK-paxillin interactions, which subsequently affect SNAP-25 levels (Rondas et al.2011, Cai et al. 2012), the β1 integrin knockout in beta-cells of adult mice seems to have a similar effect. Although there were no changes in Stx1A and Stx3, a reduction in Munc18 protein was found. Munc18 is important in stabilizing the SNARE complex at the plasma membrane, mainly through interactions
with Stx1A (Thurmond 2013). No significant changes were observed in female MIPβ1KO mRNA levels of Snap25, Vamp2, Stx1A, and Stx3. The lack of a significant finding in insulin exocytotic proteins could potentially account for the indiscernible differences seen in glucose stimulated insulin secretion in female MIPβ1KO mice. These observations show that β1 integrin is required for maintenance of normal physiological levels of insulin exocytotic machinery that are pivotal in maintaining normoglycemic levels.

4.4 Is β1 integrin required for proper islet morphology?

Even though there was a defect in insulin secretion in MIPβ1KO mice, it was important to determine the changes of islet morphology and beta-cell mass. Both male and female MIPβ1KO mice, showed a decrease in beta-cell mass. This finding is in agreement with previous literature that sees a decrease in beta-cell proliferation when integrin is knocked out in beta-cells from conception (Diaferia et al. 2013), or knocked down globally in all coll1a2 producing cells in adult mice (Riopel et al. 2011). In addition, when FAK, a key component in outside-in signalling of integrins is knocked down in beta-cells from conception a similar reduction in beta-cell mass is observed (Cai et al. 2012). To account for the reduction in beta-cell mass, cell cycle progression and apoptosis were examined. Akin to our previous publication (Riopel et al. 2011), a significant reduction in cyclin D1 was observed along with an increase in c-PARP in male MIPβ1KO mice, whereas females did not show significant changes in these markers, presumably from the protective effect of estrogen as mentioned previously. Despite only seeing a significant change in proliferation and apoptotic markers in male MIPβ1KO mice, this is most likely the cause for the decrease in beta-cell mass of female MIPβ1KO mice as well.

An interesting observation in the MIPβ1KO mice was a trend towards a decrease in alpha-cell mass in male mice, along with a significant reduction in female mice. In models of diet induced diabetes like the Goto-Kakizaki rat (Movassat et al. 1997) alpha-cell mass can be decreased when beta-cells are reduced. The defect in normal alpha-cell mass is attributed to abnormal islet-architecture from the distinct reduction in beta-cell population, which subsequently impacts cell-to-cell contacts within the islet, along with
reduced nutrient secretion and protein secretion important in eliciting normal ECM development in and around the islets.

With the overall decrease in beta-cell mass and changes in alpha-cell mass of MIPβ1KO mice, an overall examination of islet density was conducted. Male MIPβ1KO mice had fewer islets overall, which coincided with fewer medium (<500-2500µm²) and large (<2501-10000µm²) islets, and is similar to findings in Diaferia (2013). Female MIPβ1KO mice, however, had an increase in small islets (<500 µm²) despite a trend towards decreased islet density. This increase in smaller islets, which was not seen in the males, clearly resulted in a greater number of islets per mm² compared to their male counterparts. Despite these differences, it was clear that MIPβ1KO mice have altered islet morphology compared to their control littermates.

One aspect that remained to be examined was that of transcription factors required for proper beta-cell differentiation and function. Both Pdx-1 and Nkx6.1 were reduced in the β1KO model used in Riopel (2011) and have been shown to be important in beta-cell differentiation and proper maintenance and function in adult mice (McKinnon & Docherty 2011, Taylor et al. 2013). In the present study, male MIPβ1KO mice had a marked decrease in Pdx-1 mRNA and protein as assessed by qRT-PCR and western blot. However, there was no decrease in the number of Pdx-1⁺ cells beta-cells. This finding is in contrast to that of Diaferia (2013), where no change in Pdx-1 protein was observed. This could be due to the knockout of β1 integrin at conception rather than in adulthood, giving beta-cells time to engage compensatory mechanisms that account for the lack of β1 integrin and maintain normal expression levels of this transcription factor. Reduced Pdx-1 in male MIPβ1KO mice could be one factor that is responsible for the glucose intolerance, decreased insulin levels, and decreased beta-cell mass that was observed in them. Unlike the β1KO model (Riopel et al. 2011, Riopel et al. 2013), there was no change in Nkx6.1 protein in MIPβ1KO mice. The changes in ECM composition observed in these previous studies, mainly a decrease in collagen fibers and connective tissue surrounding the islets, is a potential reason why there was a decrease in Nkx6.1 as well. The shift in ECM composition created a drastically different environment for the beta-
cells to reside, and subsequently may be the reason why Nkx6.1 was decreased in β1KO and not RIPβ1KO or MIPβ1KO mice.

4.5 Vasculature in the islets of MIPβ1KO mice

Previous studies have shown that endothelial cells are required for proper deposition of the basement membrane, which in turn leads β1 integrin to promote beta-cell proliferation and insulin gene expression (Nikolova, 2006). Additionally, adequate vasculature is required for beta-cells to sense changes in blood glucose as well as provide a pathway for insulin to be released and distributed throughout the body (Brissova, 2006). It has been established that PaSCs, which are myofibroblast-like cells, can promote endothelial cell proliferation via secretion of vascular endothelial growth factor (VEGF) (McCarroll et al. 2014). Based on these findings it is not surprising that vasculature was reduced in the β1KO model used by Riopel et al. (2011), in which both PaSCs and pericytes, cells that adhere and aid in vasculature formation in addition to ECM deposition, were both lacking β1 integrin. Unlike this previous study where β1 integrin was lacking in PaSCs and pericytes, our beta-cell specific knockout did not lead to a significant impairment in endothelial cell number and overall vascularization of islets. Although, these were only qualitative studies. Despite beta-cells having a role in VEGF secretion and recruitment of endothelial cells (Nikolova et al. 2006), having normal β1 integrin levels in PaSCs and pericytes seems to overcome any deficit in VEGF-A secretion, allowing for normal islet vascularization in MIPβ1KO mice.

4.6 Signalling in MIPβ1KO mice

The role of β1 integrin in regulating FAK and its downstream signalling molecules has been examined in a multitude of different cell types, including pancreatic beta-cells and beta-like cells (e.g., INS-1 cells). Our study found a significant reduction in the phosphorylation of FAK$^{Y397}$, and this is in alignment with several studies, all of which show that β1 integrin is one regulator of phosphorylating FAK at tyrosine 397 (Hammer et al. 2004, Kaido et al. 2004, Wang et al. 2005, Krishnamurthy et al. 2008, Saleem et al. 2009, Riopel et al. 2011). FAK is responsible for regulating a multitude of downstream signalling molecules, one of which is ERK1/2, which has shown to be important in
maintaining function and survival in beta-cells and beta-like cells in vitro (Hammer et al. 2004, Krishnamurthy et al. 2008, Saleem et al. 2009) and beta-cells in vivo (Riopel et al. 2011, Cai et al. 2012). A significant reduction in phosphorylation of ERK1/2 was also found in the MIPβ1KO mice. Activation of ERK1/2 has been shown to play a role in beta-cell survival and Pdx-1 regulation (Hammer et al. 2004, Saleem et al. 2009, Krishnamurty et al. 2008, Riopel et al. 2011, Dioum et al. 2010), as well as regulating glucose-stimulated insulin secretion mediated by actin remodelling (Tomas et al. 2006, Rondas et al. 2011). One-point worth noting is the fact that the RIPβ1KO model (Diaferia et al. 2013) had a reduction in ERK1/2 but showed no overt phenotype, this is most likely attributed to compensation by other integrins as mentioned throughout this discussion, which has led to the less overt phenotype in this mouse model compared to MIPβ1KO model, where the knockout was induced in adults and not from conception. An interesting finding that was not observed in the β1KO mouse model (Riopel et al. 2011) was a decrease in pAktS473, which was also reduced in the RIPβ1KO model (Diaferia et al. 2013) and the beta-cell specific FAK knockdown model (Cai et al. 2012). Research has been published showing that FAK and Src which are downstream of integrins play a role in activation of p85 subunit of PI3K that leads to AktS473 activation (Xia et al. 2004). Akt has been shown to play a significant role in cell survival by mediated apoptotic proteins such as Bcl2 while also preventing activation of caspase-9 (Song et al. 2005). As such, this pathway could also be contributing to the reduced survival of beta-cells observed in the MIPβ1KO mouse model.

4.7 Aged MIPβ1KO mice and a lack of functional compensation by other integrins

One of the more interesting aspects of integrin signalling is the ability to have compensatory outside-in signalling through increased expression of other integrin subunits when one is impaired (Diaferia et al. 2013). The low proliferative rate of beta-cells in mammals should lead to maintenance of the β1 integrin knockdown in the majority of the beta-cell population, providing ample opportunity for compensation by other integrins within affected beta-cells (Kushner 2013). It has been shown that β3 and β5 integrins can maintain and enhance cellular differentiation when β1 integrin is either
functionally blocked or deleted at the gene level (Brunetta 2012, Guan 2001, Hirsch 1998, Jeanes 2012, Retta 1998). Diaferia (2013) reported an up-regulation of vitronectin and the laminin-5 β-chain in their RIPβ1KO model, which are known ECM ligands of the αvβ3 and α6β4 integrins, respectively. In the present study, the α3 integrin subunit, known to form a heterodimer with β1 integrin, showed no change in mRNA, whereas immunofluorescence staining showed a qualitative increase in this protein indicating a possible compensation through upregulation of α3 integrin. Interestingly the mRNA of αv and α6 was relatively low, but no difference at the protein level as assessed by immunofluorescence staining was observed. These two integrins are associated with other β subunits, indicating that loss of β1 integrin did not increase other integrin expression such as α6β4 and αV associated β subunits. Since there is no significant increase of other αβ integrin expression in MIPβ1KO islets, mice were aged to see if they could recover from the glucose intolerant phenotypes observed at their respective time points. It was clear that the initial knockout of β1 integrin at 3-4 weeks of age was significant enough to impact beta-cell function long-term, since the aged mice still displayed glucose intolerance, more-so than they did 8 and 16 weeks post-tamoxifen. Age, in addition to the initial knockdown of β1 integrin, could therefore play a factor in this increase in impaired glucose metabolism observed in the aged mice due to the lack of compensation through other integrins in the beta-cells of MIPβ1KO mice.

4.8 Limitations of the study

One of the limitations in using a mouse model is that it does not directly translate to humans. There are distinct differences in ECM composition, islet organization, diet and living conditions that all directly influence the outcomes that are observed. Regarding ECM composition, it has been shown that mice and humans, for example, have overlap in terms of laminin isoforms that they interact with (such as laminin-8), yet murine islets express laminin-10 as well, which is absent in human islets (Otonkoski et al. 2008). Such small variations in ECM composition might not seem like much, but when one compares the 804G matrix (rich in laminin-5) to commercially available Matrigel (containing Laminin-1), islet cells will differentiate in Matrigel to pancreatic ductal cells, whereas the 804G matrix does not have this effect (Gao et al. 2003, Bonner-Weir et al. 2000).
Although β1 integrin has high variability in terms of its ability to interact with a plethora of ECM ligands through the 11 different α subunits it associates with, the overlap of other integrins and differences in ECM composition and integrin expression in murine compared to human islets and beta-cells should not be dismissed.

One fundamental issue with the RIP mouse line used to drive Cre recombinase was ectopic expression found in the hypothalamus, potentially leading to differences in metabolism and energy maintenance (Wicksteed et al. 2010). Despite initial reports stating that the MIP construct was beta-cell specific (Tamarina et al. 2014), a study using more sensitive measures has detected the presence of MIP in the hypothalamus as well (Wang et al. 2014). Therefore, utilizing MIP to induce beta-cell gene knockouts face the same confounding variables as the RIP construct.

Another issue with using transgenic mouse lines is the methodology used to incorporate our transgene of interest. In the case of many transgenic mice, the human growth hormone (hGH) is included in order to increase transgene expression (Brinster et al. 1988, Palmiter et al. 1983, Palmiter et al. 1991). It was originally thought that the transgene was not transcribed and translated into growth hormone, but recent studies have shown its presence in beta-cells (Brouwers et al. 2014). The RIP-Pdx1late mouse line have lower blood glucose, increased beta-cell mass and are resistant towards STZ-induced beta-cell death due to binding of hGH to prolactin receptor which stimulates serotonin production within beta-cells (Baan et al. 2015). Within the present study, we incorporated both MIP+/β1+/+ and MIP−/β11/1 into the control group, but when strictly comparing MIP+/β1+/+ mice to MIP−/β11/1 mice, we still found that the knockdown mice were glucose intolerant at both the adult and aged time points. Despite this finding, the presence of the hGH construct should not be ignored when assessing MIPβ1KO mice and how the findings might accurately translate to human physiology.

One final limitation worth noting is that the decrease in β1 integrin was roughly ~40% in beta-cells of MIPβ1KO mice compared to controls, therefore being only a partial knockdown. Because the beta-cells still have more than 50% of remaining β1 integrin levels, the effect of a total knockdown in adult mouse beta-cells remains unknown.
Additionally, with the corresponding amount of β1 integrin protein present, it is possible this prevented any significant upregulation of other integrins in an attempt to compensate, unlike the compensation that was seen in the RIPβ1KO mouse line from conception. Overall, the effects of complete β1 integrin knockdown in adult murine beta-cells remains to be determined.

4.9 Conclusions and future directions

This study demonstrates that subnormal physiological levels of β1 integrin in the beta-cells of murine islets leads to pathological distress, more so in males then in females as previously described. The mice are unable to overcome the deficit in β1 integrin and results in impaired glucose tolerance and insulin secretory machinery. The reduction in β1 integrin leads to reduced beta-cell mass and altered islet size and density, along with increased apoptosis and decreased proliferation. The signalling pathways downstream of β1 integrin (FAK/ ERK1/2 and Akt) are also affected by reduced β1 integrin levels, leading to the observed phenotype. A summary of the key findings of this study is presented in Figure 4.1.

The overall significance of this study stems from islet transplantation as a method to treat T1D. One of the fundamental issues is a lack of donor tissue, so finding optimum conditions to reproduce native environments is of utmost importance in order to maintain survivability of isolated islets, and perhaps in the future, to maintain and reproduce stem-cell derived beta-like cells. One promising avenue is the concept of encapsulating islets, or even just beta-cells themselves, to prevent an autoimmune attack (Vegas et al. 2016). However, ensuring survival of these cells requires not only protection from the immune system, but a sustainable environment as well. The importance of the ECM has been well documented throughout this dissertation, and elucidating the role of integrin receptors and their interaction with ECM ligands is paramount in constructing a long-term cure for treatment of T1D.

One future avenue of research utilizing the MIPβ1KO model would be to assess what happens during murine embryonic development. Inducing a knockdown of β1 integrin during both the second and third phases of development will not only provide insight into
its role during the aforementioned periods, but allowing these mice to age to adults would allow time to see if the organisms can compensate for this deficit. By determining alternative pathways or proteins that can aid in maintaining the functional state of beta-cells, or determining what is absolutely required as the animals progress from embryonic to adults, one can further the knowledge required for finding ways to treat diabetes.

Finally, finding a relationship between β1 integrin and proteins involved in the SNARE complex that is essential for not only insulin secretion, but docking of integrins to the plasma membrane is a novel area of study. This study has shown that a reduction in β1 integrin affects SNAP25 and Munc18 mRNA and protein, which is a novel finding. Studies examining this relationship might provide future ideas for ways to enhance beta-cell insulin secretion through ECM or integrin interactions.
The tamoxifen induced beta-cell specific knockout of β1 integrin lead to a multitude of impairments in male MIPβ1KO mice. A reduction in the SNARE complex proteins Snap25, Vamp-2 and Munc18-1 was observed, however the mechanisms that lead to this reduction remain to be seen. A reduction in phosphorylated (P) FAK, ERK1/2 and Akt was also observed, and these proteins have been shown to play a role in mediating beta-cell proliferation, survival, and function.


Dioum EM, Schneider JW, Cobb MH. Contribution of MAP kinases ERK1/2 in beta-cell function. FASEBJ 2010;24(1):Supplmental 659.5


Hald J, Sprinkel AE, Ray M, Serup P, Wright C, Madsen OD. Generation and characterization of Ptf1a antiserum and localization of Ptf1a in relation to Nkx6.1 and


Movassat J, Saulnier C, Serradas P, Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 1997;40(8):916-925.


Rondas D, Tomas A, Halban PA. Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. Diabetes 2011;60:1146-1157.


Appendices
Appendix A: Animal use protocol

Western

2008-038-04::6:

**AUP Number:** 2008-038-04  
**AUP Title:** Pancreatic Beta Cell Development: The Role of the c-Kit and Integrin Receptors  

**Yearly Renewal Date:** 11/01/2014

The YEARLY RENEWAL to Animal Use Protocol (AUP) 2008-038-04 has been approved, and will be approved for one year following the above review date.

This AUP number must be indicated when ordering animals for this project. Animals for other projects may not be ordered under this AUP number. Purchases of animals other than through this system must be cleared through the ACVS office. Health certificates will be required.

**REQUIREMENTS/COMMENTS**

Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar with the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have received all necessary approvals. Please consult directly with your institutional safety officers.

Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee
Appendix B: Classification II laboratory approval form

<table>
<thead>
<tr>
<th>University of Western Ontario Permit Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permit Holder: Wang, Rennian</td>
</tr>
<tr>
<td>Permit #: BIO-LHRI-0046</td>
</tr>
<tr>
<td>Classification: 2</td>
</tr>
<tr>
<td>Department: Physiology</td>
</tr>
<tr>
<td>Phone:</td>
</tr>
<tr>
<td>Email:</td>
</tr>
<tr>
<td>Approval Date: Apr 25, 2014</td>
</tr>
<tr>
<td>Expiration Date: Apr 24, 2017</td>
</tr>
<tr>
<td>BioSafety Officer's Signature:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Organism</th>
<th>Cell</th>
<th>Human</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human (primary), fetal pancreas and duodenum, Rodent (primary), mouse pancreatic islets, human (established), PANC-1, HEK293, Rodent (established), INS-1, AR42J</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene Therapy</th>
<th>GMO</th>
<th>Animals</th>
<th>Toxin</th>
<th>Plant/Insect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>B6 mice</td>
<td>Streptozocin, Tamoxifen</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Building</th>
<th>Room</th>
<th>Room Area</th>
<th>Lab Phone</th>
<th>Ext.</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>OFF CAMPUS</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

April-28-14
University of Western Ontario
Permit Summary

Permit Holder: Wang, Rennian
Permit #: BIO-LHRI-0046
Classification: 2
Department: Physiology
Phone: ___________________________ Ext.
Email: ___________________________
Approval Date: Apr 25, 2014
Expiry Date: Apr 24, 2017
BioSafety Officer’s Signature: __________________________

Permit Conditions

1 INTERNAL PERMIT HOLDER RESPONSIBILITIES

Comply with UWO Biosafety Safety Policies and Standard Operating Procedures. Ensure that the Health Canada Biosafety Guidelines, relevant regulations and safe laboratory practices are followed.

1.1 Receive adequate biosafety training from the institution. Permit Holders are responsible for the provision of specific training and instruction in biohazard agent handling that is necessary for the safe use of this material in their own laboratories. Supervisors must ensure that workers understand the health and safety hazards of the work or task (due diligence).

1.2 Ensure that the UWO Biosafety Manual is available to all lab personnel under the permit.

1.3 Report incidents of loss or theft of any biohazardous material immediately to the Biosafety Coordinator;

2 WORKER RESPONSIBILITIES

Be familiar with the UWO Biosafety Manual, attend all required safety training sessions and obey all safety regulations required by the UWO Biosafety Committee.

2.1 Report to the Permit Holder any incident involving known or suspected exposure, personal contamination or a spill involving a biohazardous agent.

I accept the above responsibilities as a Internal Permit Holder and I am accountable for following UWO BioSafety Guidelines and Procedures Manual for Containment Level 1 and 2 Laboratories.

Permit Holder Name: ___________________________ Signed: ___________________________ Date: ___________________________

April-28-14
Appendix C: Biosafety approval form

April 28, 2014

Dear Dr. Wang:

Please note your biosafety approval number listed above. This number is very useful to you as a researcher working with biohazards. It is a requirement for your research grants, purchasing of biohazardous materials and Level 2 inspections.

Research Grants:
- This number is required information for any research grants involving biohazards. Please provide this number to Research Services when requested.

Purchasing Materials:
- This number must be included on purchase orders for Level 1 or Level 2 biohazards. When you order biohazardous material, use the on-line purchase ordering system (www.uwo.ca/finance/people/). In the “Comments to Purchasing” tab, include your name as the Researcher and your biosafety approval number.

Annual Inspections:
- If you have a Level 2 laboratory on campus, you are inspected every year. This is your permit number to allow you to work with Level 2 biohazards.

To maintain your Biosafety Approval, you need to:
- Ensure that you update your Biohazardous Agents Registry Form at least every three years, or when there are changes to the biohazards you are working with.
- Ensure that the people working in your laboratory are trained in Biosafety.
- Ensure that your laboratory follows the University of Western Ontario Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories.
- For more information, please see: www.uwo.ca/hr/safety/biosafety/.

Please let me know if you have questions or comments.

Regards,

Tony Hammoud
Biosafety Coordinator for Western
Curriculum Vitae

JASON PEART

EDUCATION:

Honours Double Major in Biology and Psychology, York University
Toronto, Ontario – Graduated Summer 2012.

Masters in Pathology and Laboratory Medicine, University of Western
Ontario, London, Ontario expected graduation Spring 2017

RESEARCH EXPERIENCE:

2011 Honours Thesis Research, Department of Biology, York University
Supervisor: Dr. Suraj Unniappan
Advisor: Dr. Andrew Donini

Title of the thesis: Chronic sub-cutaneous infusion of nesfatin-1 does not
affect blood glucose levels in C57BL/6 mice with type 1 diabetes

Brief description of the thesis work: C57BL/6 mice were treated with
streptozotocin and implanted with osmotic mini-pumps containing the
protein nesfatin-1. The affects of nesfatin-1 on blood glucose regulation and
pancreatic β-cell neogenesis was examined

2012 Advanced Research in Psychology, Department of Psychology, York
University
Supervisor: Dr. Janice Johnson

Title of the thesis: Does having type 1 diabetes affect desirability regarding
an intimate relationship?
Brief description of thesis work: University students were surveyed using a customized questionnaire involving online dating profiles. The purpose was to examine whether or not having type 1 diabetes impacted an individual’s likelihood of being considered as a potential romantic partner

2012 Psychology 4th Year Independent Study, Department of Psychology, York University

Supervisor: Dr. Susan MacDonald,

Title of Project: A comparison of gorilla and orangutan play behavior

Brief description of final project: Gorilla and orangutan play behaviour was examined at the Toronto Zoo over multiple weeks and comparisons were made

2013- MSc Degree in Pathology and Laboratory Medicine, University of Western Ontario

Supervisor: Dr. Rennian Wang,

Brief description of project: Examining the effect of an inducible β-cell specific, β1-integrin knockout in adult and adolescent mice

POSTER AND ORAL PRESENTATIONS:


Peart JE, Feng ZC, Riopel M, Li J, Wang R. The Effect of β1-Integrin on Pancreatic Beta-cell Survival and Function using an Inducible Beta-cell Specific β1-Integrin Knockout Mouse Model. Poster Presentation at the


CONFERENCE PUBLICATIONS:


PUBLICATIONS:

Jason Peart, Jinming Li, Hojun Lee, Matthew Riopel, Zhi-Chao Feng, Rennian Wang. Critical role of β1 integrin in postnatal beta-cell function and expansion. Oncotarget (pending revisions).